

Appendix 3: Code groups from ICPC-2 and ICPC-2 PLUS

Table A3.1: Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC/ICPC-2 PLUS label
REASONS FOR ENCOUNTER AND PROBLEMS MANAGED			
Abdominal pain	D01		Pain/cramps; abdominal general
	D06		Pain; abdominal localised; other
Abnormal test results	A91		Abnormal results investigations NOS
	B84		Abnormal white cells
	U98		Abnormal urine test NOS
	X86		Abnormal Pap smear
Anaemia	B80		Iron deficiency anaemia
	B81		Anaemia; vitamin B12/folate deficiency
	B82		Anaemia other/unspecified
Anxiety	P01		Feeling anxious/nervous/tense
	P74		Anxiety disorder/anxiety state
Arthritis		L70009	Arthritis; pyogenic
		L70010	Arthritis; viral
		L81003	Arthritis; traumatic
		L83010	Arthritis; spine cervical
		L84003	Arthritis; spine
		L84023	Arthritis; spine thoracic
		L84024	Arthritis; spine lumbar
		L84025	Arthritis; lumbosacral
		L84026	Arthritis; sacroiliac
		L89004	Arthritis; hip
		L90004	Arthritis; knee
		L91007	Arthritis; degenerative
		L91009	Arthritis
		L91010	Arthritis; acute
		L91011	Arthritis; allergic
		L91012	Polyarthritis
	L91013	Arthritis; hands/finger(s)	
	L91014	Arthritis; wrist	
	L92006	Arthritis; shoulder	
	S91002	Arthritis; psoriatic	
	T99063	Arthritis; crystal (excl. gout)	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC/ICPC-2 PLUS label
Reasons for encounter and problems managed (continued)			
Back complaint	L02		Back symptom/complaint
	L03		Low back symptom/complaint
	L86		Back syndrome with radiating pain
Check-up—all	–30		Medical examination/health evaluation, complete
	–31		Medical examination/health evaluation, partial
	X37		Pap smear
Check-up—ICPC chapter	A30; A31		General
	B30; B31		Blood
	D30; D31		Digestive
	F30; F31		Eye
	H30; H31		Ear
	K30; K31		Cardiovascular
	L30; L31		Musculoskeletal
	N30; N31		Neurological
	P30; P31		Psychological
	R30; R31		Respiratory
	S30; S31		Skin
	T30; T31		Endocrine
	U30; U31		Urology
	W30; W31		Prenatal/postnatal
	X30; X31; X37		Female genital
Y30; Y31		Male genital	
Z30; Z31		Social	
Depression	P03		Feeling depressed
	P76		Depressive disorder
Diabetes—non-gestational)	T89		Diabetes; insulin-dependent
	T90		Diabetes; non-insulin-dependent
Diabetes—all	T89		Diabetes; insulin-dependent
	T90		Diabetes; non-insulin-dependent
	W85		Gestational diabetes

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC/ICPC-2 PLUS label
Reasons for encounter and problems managed (continued)			
Fracture	L72		Fracture; radius/ulna
	L73		Fracture; tibia/fibia
	L74		Fracture; hand/foot bone
	L75		Fracture; femur
	L76		Fracture; other
		L84019	Fracture; compression; spine
		L99017	Fracture; non-union
		L99018	Fracture; pathological
		L99019	Fracture; malunion
		L99095	Fracture; stress
		N54005	Decompression; fracture; skull
		N80012	Fracture; skull (base)
		N80013	Fracture; skull
		N80014	Injury; head; fracture
Hypertension/high BP (RFEs)	K85		Elevated blood pressure without hypertension
	K86		Uncomplicated hypertension
	K87		Hypertension with involvement of target organs
		W81002	Hypertension; pre-eclamptic
		W81003	Hypertension in pregnancy
Hypertension (problems)	K86		Uncomplicated hypertension
	K87		Hypertension with involvement of target organs
		W81002	Hypertension; pre-eclamptic
		W81003	Hypertension in pregnancy
Immunisation	A44		Preventive immunisation/medication—general/unspecified
		D44002	Immunisation; typhoid
		D44003	Immunisation; mumps
		D44004	Immunisation; digestive
		D44007	Immunisation; hepatitis
		D44009	Immunisation; hepatitis A
		D44010	Immunisation; hepatitis B
		D44016	Medication; prevent; hepatitis
		D44018	Immunisation; hepatitis A & B
		N44	Preventive immunisation/medication; neurological
	R44	Preventive immunisation/medication; respiratory	
Ischaemic heart disease	K74		Ischaemic heart disease without angina
	K76		Ischaemic heart disease with angina

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC/ICPC-2 PLUS label	
Reasons for encounter and problems managed (continued)				
Menstrual problems	X02		Pain; menstrual	
	X03		Pain; intermenstrual	
	X05		Menstruation; absent/scanty	
	X06		Menstruation; excessive	
	X07		Menstruation; irregular/frequent	
	X08		Intermenstrual bleeding	
	X09		Premenstrual symptoms/complaint	
	X10		Postponement of menstruation	
	Oral contraception	W10		Contraception; postcoital
		W11		Oral contraceptive
W50			Medication; reproductive system	
Osteoarthritis		L83011	Osteoarthritis; spine; cervical	
		L84004	Osteoarthritis; spine	
		L84009	Osteoarthritis; spine; thoracic	
		L84010	Osteoarthritis; spine; lumbar	
		L84011	Osteoarthritis; lumbosacral	
		L84012	Osteoarthritis; sacroiliac	
		L89001	Osteoarthritis; hip	
		L90001	Osteoarthritis; knee	
		L91001	Osteoarthritis; degenerative	
		L91003	Osteoarthritis	
		L91008	Heberdens nodes	
		L91015	Osteoarthritis; wrist	
		L92007	Osteoarthritis; shoulder	
Pregnancy	W01		Question of pregnancy	
	W78		Pregnancy	
	W79		Unwanted pregnancy	
Prescription	-50		Medication prescription/request/renewal/injection	
Rash	S06		Localised redness/erythema/rash of skin	
	S07		Generalised/multiple redness/erythema/rash skin	
Rheumatoid arthritis	L88		Rheumatoid arthritis	
Sprain/strain		L19014	Strain; muscle(s)	
	L77		Sprain/strain; ankle	
	L78		Sprain/strain; knee	
	L79		Sprain/strain; joint NOS	
		L83023	Sprain; neck	
		L83024	Strain; neck	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 rubric	ICPC-2 PLUS code	ICPC/ICPC-2 PLUS label
Reasons for encounter and problems managed (continued)			
Sprain/strain (continued)		L83025	Whiplash injury; neck old
		L84020	Sprain; back
		L84021	Strain; back
Swelling (skin)	S04		Localised swelling/papules/ lump/mass/ skin/ tissue
	S05		Generalised swelling/papules/ lumps/mass/ skin/tissue
Test results	-60		Results test/procedures
	-61		Results examinations/test/record/letter other provider
Tonsillitis	R76		Tonsillitis; acute
	R90		Hypertrophy; tonsils/adenoids
Urinary tract infection	U70		Pyelonephritis/pyelitis
	U71		Cystitis/urinary infection other
CLINICAL TREATMENTS			
Advice/education		A45002	Advice/education
		B45002	Advice/education; blood
		D45002	Advice/education; digestive
		F45002	Advice/education; eye
		H45002	Advice/education; ear
		K45002	Advice/education; cardiovascular
		L45002	Advice/education; musculoskeletal
		N45002	Advice/education; neurological
		P45001	Advice/education; psychological
		R45002	Advice/education; respiratory
		S45002	Advice/education; skin
		T45002	Advice/education; endocrine/metabolic
		U45002	Advice/education; urology
		W45004	Advice/education; reproductive
		X45002	Advice/education; genital; female
		Y45002	Advice/education; genital; male
		Z45002	Advice/education; social
Advice/education—medication		A45015	Advice/education; medication
		A48003	Review; medication
		A48005	Increased; drug dosage
		A48006	Decreased; drug dosage
		A48007	Change (in); drug dosage
		A48008	Stop medication
		A48009	Recommend medication
	A48010	Change (in); medication	
	A48011	Medical; request; refusal	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Clinical treatments (continued)		
Advice/education—treatment	A45016	Advice/education; treatment
	A45019	Advice; time off work
	A45020	Advice; rest/fluids
	A45021	Advice; naturopathic treatment
	A48004	Review; treatment
	S45004	Advice/education; RICE
	T45004	Advice/education; diabetes
	T45009	Advice; home glucose monitoring
	Counselling/advice—alcohol	P45005
P58009		Counselling; alcohol
Counselling/advice—exercise	A45004	Advice/education; exercise
	A58005	Counselling; exercise
Counselling/advice—health/body	A45005	Advice/education; health
	A45009	Health promotion
	A45010	Information; health
	A45011	Health promotion; injury
	A45018	Advice/education; body
	A45026	Advice/education; hygiene
	A58006	Counselling; health
	A98001	Health maintenance
	Counselling/advice—lifestyle	P45008
P58012		Counselling; lifestyle
Counselling/advice—nutrition/weight	A45006	Advice/education; diet
	T45005	Advice/education; nutritional
	T45007	Advice/education; weight management
	T58002	Counselling; weight management
Counselling/advice—prevention	A45025	Advice/education; immunisation
	A58007	Counselling; prevention
	X45004	Advice/education; breast self exam
	Z45005	Advice/education; environment
Counselling/advice—smoking	P45004	Advice/education; smoking
	P58008	Counselling; smoking
Counselling—problem	A58002	Counselling; problem
	A58003	Counselling; individual
	B58001	Counselling; problem; blood/blood-forming
	D58001	Counselling; problem; digestive
	F58001	Counselling; problem; eye
	H58001	Counselling; problem; ear
	K58001	Counselling; problem; cardiovascular

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label	
Clinical treatments (continued)			
Counselling—problem (continued)	L58001	Counselling; problem; musculoskeletal	
	N58001	Counselling; problem; neurological	
	R58001	Counselling; problem; respiratory	
	S58001	Counselling; problem; skin	
	T58001	Counselling; problem; endocrine/metabolic	
	U58001	Counselling; problem; urology	
	W58003	Counselling; problem; reproductive	
	X58001	Counselling; problem; genital; female	
	X58003	Counselling; sexual; physical; female	
	Y58001	Counselling; problem; genital; male	
	Y58003	Counselling; sexual; physical; male	
	Z58002	Counselling; problem; social	
	Counselling—psychological	P58001	Counselling; psychiatric
		P58002	Psychotherapy
P58004		Counselling; psychological	
P58005		Counselling; sexual; psychological	
P58006		Counselling; individual; psychological	
P58007		Counselling; bereavement	
P58013		Counselling; anger	
P58014		Counselling; self-esteem	
P58015		Counselling; assertiveness	
P58018		Therapy; group	
P58019	Cognitive behavioural therapy		
Family planning	A98002	Counselling; genetic female	
	A98003	Counselling; genetic male	
	W14002	Family planning; female	
	W45006	Advice/education; preconceptual	
	W45007	Advice/education; contraception	
	W45008	Advice/education; family plan; female	
	W58001	Counselling; abortion	
	W58005	Counselling; terminate pregnancy	
	W58007	Counselling; preconceptual	
	W58012	Counselling; sterilisation; female	
	W58013	Counselling; family planning; female	
	Y14001	Family planning; male	
	Y45006	Advice/education; family plan; male	
	Y45007	Advice/education; contraception; female	
	Y58005	Counselling; sterilisation; male	
	Y58006	Counselling; family planning; male	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Clinical treatments (continued)		
Other admin/document	-62 (excluding sickness certificate A62008)	
Reassurance support	A58010	Reassurance/support
Sickness certificate	A62008	Admin; certificate; sickness
PROCEDURES		
Incise/drainage/flushing/aspiration/ removal body fluid	-51	
Excision/removal tissue/biopsy/ destruction/debridement/cauterisation	-52	
Repair/fixation-suture/cast/prosthetic device (apply/remove)	-54	
Local injection/infiltration	-55	
Dressing/pressure/compression/ tamponade	-56	
Physical therapy/rehabilitation	-57	
Other procedures/minor surgery NEC	-59	
CLINICAL MEASUREMENTS		
Electrical tracings	-42	
Pap smear	X37001	Pap smear
	X37003	Test; cytology; genital; female
Physical function test	-39	
Urine test	A35001	Test; urine
	A35002	Urinalysis
	B35001	Test; urine; blood
	D35001	Test; urine; digestive
	P35001	Test; urine; psychological
	T35001	Test; urine; endocrine/metabolic
	U35002	Test; urine; urology
	W35001	Test; urine; reproductive
	Y35001	Test; urine; genital; male
REFERRALS		
Allied health services	-66	Referral to other provider/nurse/therapist/ social worker
	-68 excluding A68011; Z68003 and Z68004	Other referrals NEC
	Z67002	Referral; respite care

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Referrals (continued)		
Specialist	–67 excluding A67010; A67011; A67015; P67005 and Z67002	Referral to physician/specialist/clinic/hospital
	A68009	Referral; oncologist
Emergency department	A67011	Referral; A & E
Hospital	A67010	Referral; hospital
	A67015	Referral; hospice
	P67005	Referral; hospital; psychiatrist
Other referrals	A68011	Referral
	Z68003	Referral; financial/legal services
	Z68004	Referral; police
PATHOLOGY TEST ORDERS		
Chemistry		
Amylase	D34004	Test; amylase
B12	B34015	Test; B12
	D34009	Test; Schillings
C reactive protein	A34005	Test; C reactive protein
Calcium/phosphate	A34006	Test; calcium
	A34013	Test; phosphate
	A34024	Test; calcium phosphate
Cardiac enzymes	D34005	Test; aspartate aminotransferas
	K34003	Test; cardiac enzymes
	K34004	Test; creatine kinase
	A33023	Test; alpha fetoprotein
	A33026	Test; cancer antigen 125
	A33027	Test; cancer antigen 15.3
	A33028	Test; cancer antigen 19.9
	A33029	Test; carcinoembryonic antigen
	A33041	Test; cancer antigen
	A34015	Test; protein
	A34018	Vitamin assay
	A34019	Test; lead
	A34020	Test; blood gas analysis
	A34022	Test; mineral
	A34023	Test; zinc
	A34025	Test; DHEAS
	A34030	Test; biochemistry

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label	
Pathology test orders (continued)			
Cardiac enzymes (continued)	A34031	Test; blood alcohol	
	A34032	Test; prolactin	
	A34033	Test; testosterone	
	A34037	Test; Glutathione S-transferase	
	A34038	Test; magnesium	
	A35004	Test; urine sodium	
	A35007	Test; urine; albumin	
	A35008	Test; albumin creatine ratio	
	B34023	Test; transferrin	
	D34002	Test; alanine aminotransferase	
	D35002	Test; 5-HIAA	
	K34001	Test; blood; digitalis	
	K34006	Test; amino acids	
	K34007	Test; troponin	
	Chemistry; other	N34001	Test; blood; phenylhydantoin
		P34003	Test; methadone
		T34018	Test; androgens
T34019		Test; insulin	
T34021		Test; C peptide	
T34029		Test; aldosterone	
T34030		Test; parathyroid hormone	
T35002		Test; catecholamines	
W38002		Amniocentesis	
Drug screen		A34002	Drug assay
	A34026	Blood drug screen	
	A34027	Blood screen	
	A35003	Drug screen	
	A35005	Urine drug screen	
	K34005	Test; digoxin	
	N34003	Test; phenytoin	
	N34004	Test; valproate	
	N34005	Test; carbamazepine	
	P34002	Test; lithium	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
EUC	A34007	Test; chloride
	A34008	Test; electrolytes
	A34010	Test; EUC
	A34014	Test; potassium
	A34017	Test; sodium
	A34029	Test; U&E
	A34034	Test; E&C
	U34002	Test; creatinine
	U34003	Test; urea
	HbA1c	T34010
T34017		Test; fructosamine
T34022		Test; HBA1
Ferritin	B34016	Test; ferritin
	B34019	Test; iron studies
Folic acid	B34017	Test; folic acid
	B34024	Test; folate
Glucose/tolerance	T34005	Test; glucose
	T34009	Test; glucose tolerance
	T34023	Test; glucose (fasting/random)
	T34025	Test; glucose; fasting
	T34026	Test; glucose; random
Hormone assay	A34003	Hormone assay
	D33015	Test; Anti gliadin antibody
	T33018	T33018
	T33019	T33019
	T34007	Test; cortisol
	W34005	Test; HCG
	W34006	Test; B HCG level (titre/quant)
	X34002	Test; LH
	X34003	Test; progesterone
	X34004	Test; oestradiol
	X34005	Test; FSH
	X34006	Test; SHBG; female
	X34007	Test; free androgen index; female
	Y34004	Test; SHBG; male
	Y34005	Test; free androgen index; male
Lactose intolerance	D38002	Test; lactose intolerance

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Lipids	T34001	Check-up; cholesterol
	T34004	Test; lipids profile
	T34006	Test; cholesterol
	T34011	Test; cholesterol HDL
	T34013	Test; cholesterol LDL
	T34016	Test; triglycerides
	T34020	Test; free fatty acids
	T34024	Test; chol/trig
Liver function	A34004	Test; albumin
	D34003	Test; alkaline phosphatase
	D34006	Test; bilirubin
	D34007	Test; gGT
	D34008	Test; liver function
	T34012	Test; LDH
Multibiochemical analysis	A34012	Test; multibiochemical analysis
	A34021	Test; E & LFT
Prostate specific antigen	Y34002	Test; acid phosphatase
	Y34003	Test; prostate specific antigen
Thyroid function	T34015	Test; thyroid function
	T34027	Test; thyroxine
	T34028	Test; tsh
Urate/uric acid	U34004	Test; urate/uric acid
Cytopathology		
Cytology	A37002	Test; cytology
	B37003	Test; cytology; blood
	D37002	Test; cytology; digestive
	F37002	Test; cytology; eye
	H37002	Test; cytology; ear
	K37002	Test; cytology; cardiovascular
	L37002	Test; cytology; musculoskeletal
	N37002	Test; cytology; neurological
	R37002	Test; cytology; respiratory
	R37003	Test; sputum cytology
	S37002	Test; cytology; skin
	T37002	Test; cytology; endocr/metabol
	U37002	Test; cytology; urology
	W37002	Test; cytology; reproduction
	Y37002	Test; cytology; genital; M

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label	
Pathology test orders (continued)			
Pap smear	X37001	Pap smear	
	X37003	Test; cytology; genital; F	
	X37004	Vault smear	
Haematology			
Blood grouping & typing	B33001	Test; Coombs	
	B33002	Test; blood grouping & typing	
	B33009	Test; blood group	
Blood; other	B33013	Test; blood; cross match	
	A33042	Test; lymphocyte type & count	
	A34035	Test; blood film	
	A34036	Test; blood thick film	
	B33003	RH; antibody titer	
	B34005	Test; blood; platelets	
	B34007	Test; blood; sickle cell	
	B34021	Test; reticulocyte count	
	B34031	Test; haemoglobin epg	
	B34032	Test; packed cell volume	
	B34033	Test; blood; blood	
	B37001	Exam; bone marrow	
	Coagulation	B34003	Test; coagulation time
		B34006	Test; part thromboplastin time
		B34009	Test; prothrombin time
B34014		Test; APTT	
B34022		Test; thrombin time	
B34025		Test; INR	
B34026		Test; fibrinogen	
B34028		Test; bleeding time	
B34029		Test; coagulation screen	
K34008	Test; D-Dimer		
ESR	A34009	Test; ESR	
Full blood count	A34011	Test; full blood count	
Haemoglobin	B34018	Test; haemoglobin	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Histopathology		
Histology; skin	S37001	Test; histopathology; skin
Histology; other	A37001	Test; histopathology
	B37002	Test; histopathology; blood
	D37001	Test; histopathology; digestive
	F37001	Test; histopathology; eye
	H37001	Test; histopathology; ear
	K37001	Test; histopathology; cardiovas
	L37001	Test; histopathology; musculosk
	N37001	Test; histopathology; neuro
	R37001	Test; histopathology; respirat
	T37001	Test; histopathology; endo/meta
	U37001	Test; histopathology; urology
	W37001	Test; histopathology; reproduct
	X37002	Test; histopathology; genital; F
	Y37001	Test; histopathology; genital; M
Immunology		
Anti-nuclear antibodies	L33004	Test; anti-nuclear antibodies
Immunology; other	A32001	Test; sensitivity
	A33005	Test; immunology
	A33011	Test; HLA
	A33024	Test; bone marrow surface mark
	A33025	Test; serum electrophoresis
	A38004	Test; DNA
	B33005	Test; immunology; blood
	B33007	Test; immunoglobulins
	B33011	Test; IgE
	B34027	Test; FBC for surface markers
	B34030	Test; intrinsic factor
	D32001	Test; sensitivity; digestive
	D33004	Test; immunology; digestive
	D33014	Test; endomysial antibody
	D33028	Test; mitochondrial antibodies
	F33002	Test; immunology; eye
	H33002	Test; immunology; ear
	K33002	Test; immunology; cardiovascular
	K33003	Test; ANCA

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Immunology; other (continued)	L33003	Test; immunology; musculoskel
	L34001	Test; lupus erythemat; cell prep
	N33002	Test; immunology; neurological
	R32004	Test; sensitivity; respiratory
	R33004	Test; immunology; respiratory
	S32001	Test; sensitivity; skin
	S33002	Test; immunology; skin
	S33004	Test; skin patch
	T33002	Test; immunology; endoc/metabol
	U33003	Test; immunology; urology
	W33007	Test; immunology; reproductive
	X33002	Test; immunology; genital; F
	Y33002	Test; immunology; genital; M
	RAST	A34016
Rheumatoid factor	L33001	Test; rheumatoid factor
Infertility/pregnancy	W33001	Test; urine; pregnancy
	W33002	Test; pregnancy
	W34002	Test; blood; pregnancy
	W34003	Test; antenatal
	W34007	Test; pregnancy screen
	W35003	Test; urine; HCG
	Y38002	Test; sperm count
	Y38003	Test; semen examination
Microbiology		
Antibody	A33003	Test; antibody
Cervical swab	X33004	Test; cervical swab M&C
Chlamydia	A33006	Test; chlamydia
	A33034	Test; chlamydia direct immunofl
	X33006	Test; viral culture; genital; F
Ear swab and C&S	H33003	Test; ear swab M&C
Faeces MC&S	D33002	Stool(s); culture
	D33008	Test; faeces M&C
	D36001	Test; faeces; cyst/ova/parasite
Fungal ID/sensitivity	A33008	Test; fungal ID/sensitivity
	A33030	Test; skin scraping fungal M&C

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Hepatitis serology	D33005	Test; hepatitis A serology
	D33006	Test; hepatitis B serology
	D33007	Test; hepatitis C serology
	D33013	Test; hepatitis serology
	D33018	Test; hepatitis A antibody
	D33019	Test; hepatitis B antibody
	D33020	Test; hepatitis D antibody
	D33021	Test; hepatitis E antibody
	D33022	Test; hepatitis A antigen
	D33023	Test; hepatitis C antigen
	D33024	Test; hepatitis D antigen
	D33025	Test; hepatitis E antigen
	D33026	Test; hepatitis antibody
	D33027	Test; hepatitis antigen
	HIV	A33021
B33006		Test; HIV
B33008		Test; AIDS screen
B33012		Test; HIV viral load
H pylori	D33009	Test; H Pylori
Microbiology; other	A33004	Test; microbiology
	A33007	Test; culture and sensitivity
	A33012	Test; mycoplasma serology
	A33013	Test; parvovirus serology
	A33015	Test; Barmah forest virus
	A33016	Test; Antistreptolysin O Titre
	A33017	Test; herpes simplex culture
	A33019	Test; herpes simplex serology
	A33020	Test; toxoplasmosis serology
	A33033	Test; swab M&C
	A33035	Test; serology
	A33036	Antibodies screen
	A33038	Test; rapid plasma regain
	A33039	Test; viral swab M&C
	A33040	Test; viral serology
	A33043	Test; HPV
A33044	Test; Brucella	
A33045	Test; fungal M&C	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Microbiology; other (continued)	A33046	Test; measles virus antibodies
	A33047	Test; Rickettsial serology
	A34028	Test; blood culture
	A34039	Test; Q fever
	B33004	Test; microbiology; blood
	B33010	Test; serum immunoglobulins
	D33003	Test; microbiology; digestive
	D33010	Test; hepatitis D serology
	D33011	Test; hepatitis E serology
	D33012	Test; rotavirus
	D33016	Test; hepatitis C antibody
	D33017	Test; hepatitis B antigen
	F33001	Test; microbiology; eye
	F33003	Test; eye swab M&C
	H33001	Test; microbiology; ear
	K33001	Test; microbiology; cardiovascul
	L33002	Test; microbiology; musculoskel
	N33001	Test; microbiology; neurological
	R33001	Culture; tuberculosis
	R33002	Culture; throat
	R33003	Test; microbiology; respiratory
	R33009	Test; influenza serology
	R33010	Test; Legionnaires antibodies
	R33011	Test; RSV
	S33001	Test; microbiology; skin
	S33005	Test; varicella zoster serology
	S33006	Test; varicella zoster culture
	S33007	Test; nail M&C
	T33001	Test; microbiology; endoc/metabo
	U33002	Test; microbiology; urology
	W34004	Test; antenatal serology
	W33006	Test; microbiology; reproductive
	X33001	Test; microbiology; genital; F
	X33003	Culture; gonococcal; F
	Y33001	Test; microbiology; genital; M
	Y33003	Culture; gonococcal; M
	Y33004	Test; viral culture; genital; M
	Y33005	Test; urethral/penile swab

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Monospot	A33002	Test; monospot
	A33014	Test; Paul Bunnell
	A33031	Test; Epstein Barr virus serol
	A33032	Test; Epstein Barr virus
Nose swab C&S	R33008	Test; nose swab M&C
Pertussis	R33007	Test; pertussis
Ross River fever	A33009	Test; Ross River Fever
Rubella	A33001	Test; rubella
Skin swab C&S	S33003	Test; skin swab M&C
Sputum C&S	R33005	Test; sputum M&C
Throat swab C&S	R33006	Test; throat swab M&C
Urine MC&S	U33001	Test; culture; urine
	U33004	Test; urine M&C
Vaginal swab and C&S	X33005	Test; vaginal swab M&C
Venereal disease	A33010	Test; venereal disease
	A33022	Test; syphilis serology
Simple test; other	R32002	Test; tuberculin
	B35001	Test; urine; blood
	D36003	Test; occult blood
	R32001	Test; Mantoux
Other NEC		
Blood test	A34001	Test; blood
Urine test	A35001	Test; urine
Urinalysis	A35002	Urinalysis
Faeces test	A36001	Test; faeces
Other pathology test NEC	A35006	Test; urine; FWT
	A38001	Test; other lab
	A38002	Pathology
	A38003	Test; genetic
	A38005	Test; disease screen
	B38001	Test; other lab; blood
	D34001	Test; blood; digestive
	D35001	Test; urine; digestive
	D36002	Test; faeces; digestive
	D38001	Test; other lab; digestive
	F34001	Test; blood; eye
	F38001	Test; other lab; eye
	H34001	Test; blood; ear

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Pathology test orders (continued)		
Other pathology test NEC (continued)	H38001	Test; other lab; ear
	K34002	Test; blood; cardiovascular
	K38001	Test; other lab; cardiovascular
	L34003	Test; blood; musculoskeletal
	L38001	Test; other lab; musculoskeletal
	N34002	Test; blood; neurological
	N38001	Test; other lab; neurological
	P34001	Test; blood; psychological
	P35001	Test; urine; psychological
	P38001	Test; other lab; psychological
	R34001	Test; blood; respiratory
	R38001	Test; other lab; respiratory
	S34001	Test; blood; skin
	S38001	Test; other lab; skin
	T34002	Test; blood; endocr/metabolic
	T35001	Test; urine; endocrine/metabolic
	T38001	Test; other lab; endocr/metabol
	U34001	Test; blood; urology
	U35002	Test; urine; urology
	U38001	Test; other lab; urology
	W34001	Test; blood; reproductive
	W35001	Test; urine; reproductive
	W38001	Test; other lab; reproductive
	X34001	Test; blood; genital; F
	X35001	Test; urine; genital; F
	X38001	Test; other lab; genital; F
	Y34001	Test; blood; genital; M
	Y35001	Test; urine; genital; M
	Y38001	Test; other lab; genital; M
	Z38001	Test; other lab; social
IMAGING TEST ORDERS (MBS)		
Diagnostic radiology	A41001	Radiology; diagnostic
	A41002	X-ray; chest
	A41006	X-ray; abdomen
	A41007	Imaging other
	A41010	Radiology
	A41014	Test; imaging; contrast/special
	B41001	Radiology; diagnostic; blood

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Treatment group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Diagnostic radiology (continued)	D41001	GI series
	D41003	Radiology; diagnostic; digestive
	D41006	X-ray; oesophagus
	D41007	X-ray; biliary ducts
	D41008	X-ray; digestive tract
	D41009	X-ray; mouth
	D41012	X-ray; dental
	D41015	Barium enema
	D41016	Barium meal
	D41017	Barium swallow
	F41001	Radiology; diagnostic; eye
	F41002	X-ray; eye
	H41001	Radiology; diagnostic; ear
	H41002	X-ray; ear
	K41002	Radiology; diagnostic; cardiovas
	K41003	Cardiogram
	K41005	Angiography; coronary
	K41006	Angiography; femoral
	K41007	Angiography; cerebral
	K41011	Angiogram
	K41012	Angiogram; coronary
	K41013	Angiogram; cerebral
	K41014	Angiogram; femoral
	L41001	Arthrogram
	L41002	Scan; bone(s)
	L41003	X-ray; bone(s)
	L41004	Plain x-ray; bone(s)
	L41005	Radiology; diagnostic; musculo
	L41013	X-ray; elbow
	L41014	X-ray; hand
	L41015	X-ray; wrist
	L41016	X-ray; knee
	L41017	X-ray; hip
	L41018	X-ray; neck
	L41019	X-ray; pelvis
	L41020	X-ray; shoulder
	L41021	X-ray; lumbosacral
	L41022	X-ray; cervical

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Diagnostic radiology (continued)	L41023	X-ray; thoracic
	L41024	X-ray; spinal
	L41025	X-ray; joint(s)
	L41026	X-ray; foot/feet
	L41027	X-ray; ankle
	L41028	X-ray; leg
	L41029	X-ray; ribs
	L41030	X-ray; face
	L41032	X-ray; arm
	L41033	X-ray; spine; lumbar
	L41034	X-ray; spine; sacrum
	L41035	X-ray; spine; coccyx
	L41036	X-ray; finger(s)/thumb
	L41037	X-ray; toe(s)
	L41038	X-ray; heel
	L41039	X-ray; tibia/fibula
	L41040	X-ray; femur
	L41041	X-ray; radius/ulna
	L41042	X-ray; clavicle
	L41043	X-ray; humerus
	L41044	X-ray; jaw
	L41045	X-ray; temporomandibular joint
	L41060	X-ray; spine; cervicothoracic
	L41061	X-ray; spine; sacrococcygeal
	L41062	X-ray; spine; thoracolumbar
	L41063	X-ray; back
	L41064	X-ray; back lower
	L41065	X-ray; forearm
	L41066	X-ray; leg lower
	L41067	X-ray; metacarpal
	L41068	X-ray; metatarsal
	L43003	Test; bone marrow density
	N41001	Radiology; diagnostic neurolog
	N41004	X-ray; skull
	P41001	Radiology; diagnostic; psychol
	R41001	Radiology; diagnostic; respirat
	R41002	X-ray; sinus
	R41003	X-ray; nose

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label	
Imaging test orders (continued)			
Diagnostic radiology (continued)	S41001	Radiology; diagnostic; skin	
	T41001	Radiology; diagnostic; endo/meta	
	T41003	X-ray; endo/metabolic	
	U41001	Pyelogram; intravenous	
	U41002	Pyelogram; retrograde	
	U41005	Radiology; diagnostic; urology	
	U41007	X-ray; urinary tract	
	U41008	X-ray; kidney/ureter/bladder	
	W41002	Radiology; diagnostic; reprod	
	W41003	X-ray; uterus	
	X41001	Mammography; female	
	X41002	Mammography; request; female	
	X41003	Thermography; breast	
	X41005	Radiology; diagnostic; genital; female	
	X41007	X-ray; breast; female	
	Y41001	Radiology; diagnostic; genital; male	
	Ultrasound	A41012	Ultrasound
		A41015	Ultrasound; abdomen
		A41017	Ultrasound; chest
		A41021	Ultrasound; inguinal
		A41022	Ultrasound; abdomen; upper
		A41023	Ultrasound; abdomen; lower
		B41002	Ultrasound; spleen
D41013		Ultrasound; gallbladder	
D41014		Ultrasound; liver	
K41001		Echocardiography	
K41016		Ultrasound; cardiac	
K43003		Test; Doppler	
K43004		Test; Doppler carotid	
K43005		Scan; duplex	
L41046		Ultrasound; neck	
L41047		Ultrasound; pelvis	
L41048		Ultrasound; shoulder	
L41049	Ultrasound; spine		
L41050	Ultrasound; knee		
L41051	Ultrasound; elbow		
L41070	Ultrasound; wrist		
L41071	Ultrasound; ankle		

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label	
Imaging test orders (continued)			
Ultrasound (continued)	L41072	Ultrasound; groin	
	L41073	Ultrasound; back	
	L41074	Ultrasound; back lower	
	L41075	Ultrasound; hand/finger(s)	
	L41076	Ultrasound; foot/toe(s)	
	L41078	Ultrasound; arm	
	L41079	Ultrasound; leg	
	N41005	Ultrasound; brain	
	N41007	Ultrasound; head	
	T41004	Ultrasound; thyroid	
	U41009	Ultrasound; renal tract	
	U41010	Ultrasound; kidney	
	W41004	Ultrasound; obstetric	
	X41009	Ultrasound; breast; female	
	X41011	Ultrasound; uterus (not preg)	
	Y41005	Ultrasound; prostate	
	Y41006	Ultrasound; scrotum	
	Y41008	Ultrasound; breast; male	
	Computerised tomography	A41013	CT scan
		A41016	CT scan; abdomen
A41018		CT scan; chest	
A41019		CT scan; abdomen; upper	
A41020		CT scan; abdomen; lower	
D41018		CT scan; liver	
K41017		CT scan; cardiac	
L41052		CT scan; neck	
L41053		CT scan; pelvis	
L41054		CT scan; spine	
L41055		CT scan; spine; cervical	
L41056		CT scan; spine; thoracic	
L41057		CT scan; spine; lumbar	
L41058		CT scan; spine; lumbosacral	
L41059		CT scan; spine; sacrum	
L41069		CT scan; spine; thoracolumbar	
L41077		CT scan; spine; cervicothoracic	
L41080		CT scan; leg	
N41006		CT scan; brain	
N41008		CT scan; head	

(continued)

Table A3.1 (continued): Code groups from ICPC-2 and ICPC-2 PLUS

Group	ICPC-2 PLUS code	ICPC-2 PLUS label
Imaging test orders (continued)		
Computerised tomography (continued)	R41004	CT scan; sinus
	X41010	CT scan; breast; female
	Y41007	CT scan; breast; male
Nuclear medicine	A41009	Nuclear medicine
	A41011	Isotope scan
	K41015	Scan; thallium heart
	R41005	Scan; VQ (lung)
Magnetic resonance imaging	A41008	MRI

Note: NOS—not otherwise specified; NEC—not elsewhere classified; A & E—accident and emergency; – (code) signifies that the concept includes all of the specified code across all chapters of ICPC-2 (excluding the Z social chapter).

Appendix 4: Summary of annual results 1998–99 to 2002–03

Table A4.1: GP characteristics, summary of annual results BEACH 1998–99 to BEACH 2002–03

GP characteristic	1998–99		1999–00		2000–01		2001–02		2002–03		5 years	
	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =984)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,047)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =999)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =983)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,008)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =5,021)
Sex (missing)	(0)	—	(0)	—	(0)	—	(0)	—	(0)	—	(0)	—
Male	689	70.0	729	69.6	683	68.4	631	64.2	653	64.8	3,385	67.4
Female	295	30.0	318	30.4	316	31.6	352	35.8	355	35.2	1,636	32.6
Age (missing)	(4)	—	(4)	—	(9)	—	(1)	—	(0)	—	(18)	—
< 35 years	62	6.3	88	8.4	67	6.7	70	7.1	74	7.3	361	7.2
35–44 years	356	36.3	338	32.4	284	28.4	263	26.8	268	26.6	1,509	30.2
45–54 years	315	32.1	338	32.4	342	34.2	359	36.5	355	35.2	1,710	34.2
55+ years	247	25.2	279	26.7	297	29.7	290	29.5	311	30.9	1,423	28.4
Years in general practice (missing)	(12)	—	(8)	—	(6)	—	(4)	—	(6)	—	(36)	—
<2 years	8	0.8	7	0.7	5	0.5	3	0.3	6	0.6	29	0.6
2–5 years	59	6.1	83	8.0	64	6.4	71	7.2	75	7.5	352	7.1
6–10 years	167	17.2	166	15.9	137	13.7	132	13.4	135	13.5	737	14.8
11–19 years	328	33.7	331	31.9	299	29.9	279	28.4	281	28.0	1,518	30.5
20+ years	410	42.2	452	43.5	488	48.8	494	50.3	505	50.4	2,349	47.1
Sessions per week (missing)	(12)	—	(6)	—	(16)	—	(15)	—	(8)	—	(58)	—
<6 per week	121	12.4	159	15.3	159	15.9	157	16.0	187	18.7	784	15.8
6–10 per week	666	68.5	691	66.0	662	66.3	666	67.8	679	67.9	3,362	67.7
11+ per week	185	19.0	191	18.3	162	16.2	145	14.8	134	13.4	817	16.5

(continued)

Table A4.1 (continued): GP characteristics, summary of annual results BEACH 1998–99 to BEACH 2002–03

GP characteristic	1998–99		1999–00		2000–01		2001–02		2002–03		5 years	
	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =984)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,047)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =999)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =983)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,008)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =5,021)
Size of practice (missing)	(62)	—	(5)	—	(28)	—	(4)	—	(8)	—	(121)	—
Solo	165	17.9	189	18.1	187	19.3	150	15.3	137	13.7	826	16.9
2–4 GPs	398	43.2	480	46.1	375	38.6	390	39.7	384	38.4	1,920	39.2
5+ GPs	359	38.9	373	35.8	409	42.1	439	44.7	479	47.9	2,154	44.0
Place of graduation (missing)	(4)	—	(2)	—	(0)	—	(0)	—	(0)	—	(35)	—
Australia	750	76.5	767	73.3	726	72.7	748	76.1	726	72.6	3,713	74.3
UK	88	9.0	89	8.5	82	8.2	75	7.6	92	9.1	425	8.5
Asia	84	8.6	99	9.4	47	4.7	85	8.6	100	9.9	414	8.3
Europe	24	2.4	20	1.9	19	1.9	18	1.8	16	1.6	90	1.8
Africa	15	1.5	25	2.4	15	1.5	36	3.7	43	4.3	128	2.6
New Zealand	11	1.1	16	1.5	15	1.5	5	0.5	22	2.2	68	1.4
Other	8	0.9	29	2.8	95	9.5	16	1.6	9	0.9	148	3.0
Practice location (missing)	(0)	—	(0)	—	(0)	—	(1)	—	(0)	—	(0)	—
Capital	671	68.2	683	65.2	680	68.1	681	69.3	652	64.7	3,367	67.1
Other metropolitan	74	7.5	77	7.4	69	6.9	80	8.1	86	8.5	386	7.7
Large rural	61	6.2	80	7.6	55	5.6	58	5.9	51	5.1	305	6.1
Small rural	60	6.1	65	6.2	56	5.6	48	4.9	78	7.7	307	6.1
Other rural	108	11.0	128	12.2	122	12.2	103	10.5	121	12.0	582	11.6
Remote central	5	0.5	4	0.4	10	1.0	4	0.5	6	0.6	30	0.6
Other remote, offshore	5	0.5	10	1.0	7	0.7	8	0.8	14	1.4	44	0.9

(continued)

Table A4.1 (continued): GP characteristics, summary of annual results BEACH 1998–99 to BEACH 2002–03

GP characteristic	1998–99		1999–00		2000–01		2001–02		2002–03		5 years	
	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =984)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,047)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =999)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =983)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =1,008)	<i>n</i> ^(a)	Per cent of GPs (<i>n</i> =5,021)
More than 50% consultations in Languages other than English	111	11.3	105	10.6	135	13.5	351	11.6*
Currently in RACGP Training Program	21	2.2	23	2.2	25	2.5	25	2.5	28	2.9	122	2.5
Completed RACGP Training Program	289	30.4	348	43.5	316	31.6	375	38.1	377	39.5	1,705	34.0
Fellow of RACGP	263	27.3	325	31.0	314	31.4	345	35.1	355	35.5	1,602	32.2
Own or co-operative after-hours arrangements	646	64.7	550	56.0	551	55.2	1,747	58.4*
Computer use	873	87.4	883	89.7	920	91.3	2,676	59.5*

(a) Missing data removed.

* Percentages based on 3 year denominator.

Table A4.2: Summary of morbidity and management, summary of annual results BEACH 1998–99 to BEACH 2002–03

Variable	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters (95% CI) (n=96,901)	Rate per 100 encounters (95% CI) (n=104,856)	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=96,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=502,100)
Reasons for encounter	146.3 (140.8–151.8)	148.5 (146.7–150.2)	151.0 (149.2–152.8)	149.2 (147.4–150.9)	150.9 (149.0–152.7)	150.2 (149.5–150.8)
Problems managed	145.3 (143.5–147.2)	146.7 (144.9–148.6)	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	148.1 (147.3–148.9)
New problems	54.5 (53.0–56.0)	45.3 (43.6–46.9)	47.4 (45.7–49.0)	55.1 (53.8–56.5)	57.0 (55.6–58.3)	51.2 (50.6–51.8)
Work-related	4.0 (3.7–4.3)	3.2 (2.9–3.5)	3.3 (3.1–3.6)	3.0 (2.7–3.2)
Medications	109.7 (107.4–112.0)	110.1 (107.8–112.4)	108.2 (105.7–110.6)	104.5 (102.2–106.9)	103.8 (101.4–106.2)	106.5 (105.5–107.5)
Prescribed	93.6 (91.2–96.1)	93.8 (91.5–96.2)	92.3 (89.9–94.7)	88.0 (85.6–90.4)	84.3 (81.8–86.9)	89.4 (88.4–90.4)
Advised OTC	8.8 (8.0–9.6)	9.4 (8.6–10.2)	9.0 (8.1–9.8)	8.9 (8.1–9.6)	10.2 (9.2–11.1)	9.0 (8.7–9.2)
GP supplied	7.3 (6.3–8.3)	6.9 (5.8–7.9)	6.9 (5.7–8.1)	7.6 (6.3–9.0)	9.3 (7.6–11.0)	8.1 (7.7–8.5)
Non-pharmacological treatments	43.2 (41.3–45.0)	46.0 (44.1–47.8)	49.4 (47.1–51.7)	51.9 (49.6–54.2)	51.8 (49.3–54.3)	50.9 (50.0–51.8)
Clinical	31.4 (29.7–33.0)	33.5 (31.8–35.2)	37.2 (35.1–39.3)	38.1 (36.1–40.1)	37.2 (35.0–39.4)	37.1 (36.3–37.9)
Procedural	11.8 (11.2–12.5)	12.5 (11.9–13.0)	12.2 (11.6–12.8)	13.8 (13.1–14.5)	14.6 (13.9–15.3)	13.8 (13.5–14.1)
Referrals	11.2 (10.8–11.6)	11.2 (10.8–11.7)	10.4 (10.0–10.8)	10.5 (10.1–10.9)	11.1 (10.7–11.6)	..
Specialist	7.4 (7.1–7.7)	7.3 (7.0–7.6)	7.4 (7.1–7.7)	7.3 (7.0–7.6)	7.7 (7.3–8.0)	..
Allied health services*	3.0 (2.8–3.2)	3.1 (2.9–3.4)	2.3 (2.1–2.5)	2.6 (2.3–2.9)	2.5 (2.3–2.8)	..
Hospital	0.7 (0.6–0.9)	0.7 (0.5–0.9)	0.5 (0.3–0.7)	0.4 (0.3–0.6)	0.6 (0.3–0.8)	..
Emergency department	0.1 (0.0–0.6)	0.1 (0.0–0.4)	0.1 (0.0–0.4)	0.1 (0.0–0.4)	0.1 (0.0–0.4)	..
Other referrals*	0.1 (0.0–0.6)	0.3 (0.0–0.6)	0.3 (0.0–0.5)	..
Pathology ⁺	24.6 (23.5–25.7)	26.3 (25.2–27.5)	29.7 (28.4–30.9)	31.0 (29.7–32.4)	32.9 (31.5–34.4)	..
Imaging**	7.1 (6.8–7.5)	7.5 (7.1–7.8)	7.7 (7.3–8.0)	7.9 (7.6–8.2)	8.6 (8.2–9.0)	..
Other investigations**	0.6 (0.4–0.8)	0.9 (0.8–1.0)	1.0 (0.8–1.2)	..

* In the first 2 years 'allied health services' and 'other referrals' were grouped together and reported together.

+ In the third year of BEACH the data collection and data coding system for pathology changed.

** In the first 2 years 'Imaging' and 'other investigations' were grouped and reported together.

Note: CI—confidence interval; UK—United Kingdom.

Table A4.3: Type of encounter, summary of annual results BEACH 1998–99 to BEACH 2002–03

Variable	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters (95% CI) (n=96,901)	Rate per 100 encounters (95% CI) (n=104,856)	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=96,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=502,100)
Direct consultations	96.7 (96.4–97.0)	96.7 (96.3–97.0)	98.1 (97.8–98.4)	97.7 (97.4–98.0)	98.4 (98.2–98.6)	97.1 (96.9–97.2)
No charge	0.8 (0.4–1.2)	0.6 (0.3–0.8)	0.6 (0.0–1.5)	0.6 (0.2–1.1)	0.5 (0.2–0.8)	0.7 (0.6–0.8)
Medicare-claimable	90.3 (89.3–91.2)	93.0 (92.4–93.5)	94.6 (94.2–95.0)	93.9 (93.5–94.4)	95.0 (94.6–95.3)	92.6 (92.3–92.9)
Short surgery consultations	1.4 (0.9–1.8)	1.3 (0.6–2.1)	1.5 (0.5–2.5)	1.0 (0.5–1.6)	1.1 (0.6–1.7)	1.2 (1.1–1.3)
Standard surgery consultations	76.3 (75.2–77.5)	78.1 (77.1–79.1)	79.4 (78.4–80.3)	79.0 (78.0–79.9)	78.7 (77.6–79.7)	75.2 (74.7–75.7)
Long surgery consultations	7.0 (6.4–7.6)	8.1 (7.4–8.7)	8.4 (7.7–9.0)	8.1 (7.5–8.7)	9.1 (8.5–9.7)	9.6 (9.3–9.9)
Prolonged surgery consultations	0.5 (0.0–1.5)	0.6 (0.1–1.0)	0.6 (0.0–1.2)	0.6 (0.0–1.2)	0.7 (0.0–1.5)	1.0 (0.8–1.1)
Home visits	1.8 (1.2–2.3)	1.4 (0.8–1.9)	1.5 (0.5–2.4)	1.5 (0.8–2.2)	1.3 (0.4–2.1)	1.7 (1.6–1.9)
Hospital	0.4 (0.0–1.8)	0.4 (0.0–2.2)	0.2 (0.0–1.7)	0.2 (0.0–1.4)	0.4 (0.0–2.7)	0.4 (0.3–0.5)
Nursing home	0.8 (0.0–1.6)	0.9 (0.0–1.8)	0.7 (0.0–2.1)	0.9 (0.0–2.4)	1.2 (0.0–2.9)	1.0 (0.9–1.1)
Case conference	0.0 (0.0–2.3)	0.0 (0.0–1.4)	..
Care plans	0.1 (0.0–1.7)	0.1 (0.0–1.0)	..
Health assessments	0.1 (0.0–0.7)	0.1 (0.0–0.6)	..
Other items	2.2 (1.7–2.7)	2.1 (1.6–2.6)	2.4 (1.3–3.5)	2.4 (1.4–3.5)	2.3 (1.1–3.5)	..
Workers compensation	1.9 (1.6–2.1)	2.0 (1.7–2.3)	2.1 (1.8–2.4)	2.0 (1.8–2.3)	1.9 (1.6–2.2)	1.9 (1.8–2.0)
Other paid (hospital, State, etc.)	3.7 (1.7–5.7)	1.2 (0.0–2.8)	0.8 (0.0–1.6)	1.1 (0.2–2.0)	1.0 (0.2–1.8)	1.8 (1.6–2.1)
Indirect consultations	3.3 (2.8–3.8)	3.3 (2.8–3.8)	1.9 (1.2–2.6)	2.3 (1.8–2.8)	1.6 (1.2–2.0)	2.9 (2.8–3.1)

Note: CI—confidence interval.

Table A4.4: Characteristics of the patients at encounters, summary of annual results BEACH 1998–99 to BEACH 2002–03

Patient variable	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Per cent of encounters (95% CI) (n=96,901)	Per cent of encounters (95% CI) (n=104,856)	Per cent of encounters (95% CI) (n=99,307)	Per cent of encounters (95% CI) (n=96,973)	Per cent of encounters (95% CI) (n=100,987)	Per cent of encounters (95% CI) (n=502,100)
Sex						
Male	42.3 (41.6–43.0)	42.7 (42.0–43.5)	42.9 (42.2–43.6)	42.6 (41.9–43.3)	42.2 (41.4–42.9)	40.9 (40.5–41.2)
Female	57.7 (57.0–58.4)	57.3 (56.5–58.0)	57.1 (56.4–57.8)	57.4 (56.7–58.1)	57.8 (57.0–58.6)	59.1 (58.8–59.5)
Age group						
< 1 year	2.4 (2.2–2.7)	2.4 (2.2–2.5)	2.1 (1.9–2.4)	2.0 (1.8–2.1)	1.9 (1.8–2.1)	2.1 (2.1–2.2)
1–4 years	5.7 (5.3–6.0)	5.2 (4.9–5.5)	5.4 (5.1–5.7)	4.9 (4.6–5.2)	5.0 (4.7–5.3)	4.9 (4.8–5.0)
5–14 years	7.7 (7.3–8.1)	7.2 (6.9–7.5)	6.8 (6.4–7.2)	6.4 (6.1–6.7)	6.6 (6.3–6.9)	6.4 (6.3–6.6)
15–24 years	9.8 (9.4–10.2)	10.4 (9.9–10.8)	10.3 (9.8–10.7)	9.5 (9.1–10.0)	10.1 (9.7–10.4)	9.9 (9.7–10.1)
25–44 years	26.0 (25.3–26.7)	26.3 (25.5–27.0)	26.3 (25.6–27.0)	25.8 (25.1–26.5)	25.7 (24.9–26.4)	25.9 (25.6–26.2)
45–64 years	24.4 (23.8–25.0)	24.5 (24.0–25.0)	26.1 (25.5–26.7)	26.3 (25.7–26.8)	26.5 (25.9–27.0)	25.7 (25.4–25.9)
65–74 years	12.3 (11.7–12.8)	12.0 (11.5–12.5)	11.7 (11.2–12.2)	12.3 (11.8–12.8)	11.6 (11.1–12.0)	12.1 (11.9–12.3)
75+ years	11.7 (11.1–12.4)	12.1 (11.4–12.9)	11.3 (10.7–12.0)	12.8 (12.0–13.5)	12.7 (11.9–13.4)	13.0 (12.7–13.3)
Other characteristics						
New patient to practice	9.2 (8.6–9.8)	7.3 (6.6–8.0)	8.0 (7.1–8.8)	9.2 (8.5–9.9)	9.9 (9.0–10.8)	9.2 (8.9–9.5)
Commonwealth health care card	47.3 (45.8–48.8)	38.6 (37.0–40.2)	36.7 (35.1–38.3)	41.9 (40.4–43.3)	40.4 (38.8–41.9)	39.3 (38.7–39.9)
Veterans' Affairs card ^(a)	3.0 (2.7–3.3)	2.6 (2.3–2.9)	3.1 (2.8–3.4)	3.3 (3.0–3.6)	3.3 (3.0–3.6)	3.4 (3.3–3.5)
Non-English-speaking background	14.5 (13.0–16.7)	7.1 (3.0–11.2)	8.0 (4.8–11.1)	9.3 (5.9–12.7)	10.6 (7.8–13.4)	8.8 (8.3–9.3)
Aboriginal person	1.0 (0.3–1.8)	0.7 (0.0–2.5)	0.7 (0.0–1.5)	0.9 (0.0–2.0)	0.8 (0.0–1.7)	1.0 (0.8–1.1)
Torres Strait Islander	0.1 (0.0–0.5)	0.1 (0.0–1.3)	0.1 (0.0–0.7)	0.1 (0.0–0.5)	0.1 (0.0–0.9)	0.1 (0.1–0.1)

(a) The 1998–99 and 1999–00 results reported here are for gold card holders only.

Note: CI—confidence interval.

Table A4.5: Rate of patient reasons for encounter (RFEs) by ICPC-2 chapter, summary of annual results BEACH 1998–99 to BEACH 2002–03

Reasons for encounter	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=502,100)
General & unspecified	26.6 (25.7–27.4)	29.0 (28.1–29.9)	28.3 (27.5–29.1)	30.9 (29.9–31.8)	34.6 (33.6–35.6)	31.1 (30.7–31.5)
Respiratory	24.8 (24.0–25.6)	25.3 (24.3–26.2)	24.6 (23.7–25.4)	23.4(22.6–24.2)	23.0 (22.0–24.0)	22.7 (22.4–23.0)
Musculoskeletal	16.7 (16.1–17.4)	16.6 (16.1–17.1)	17.7 (17.1–18.2)	16.7 (16.1–17.3)	17.7 (17.2–18.3)	16.9 (16.7–17.2)
Skin	15.1 (14.6–15.5)	15.1 (14.7–15.6)	15.5 (15.0–16.0)	14.4 (13.9–14.9)	14.7 (14.3–15.2)	15.0 (14.8–15.2)
Circulatory	11.4 (10.9–12.0)	11.2 (10.6–11.8)	11.7 (11.1–12.2)	11.4 (10.8–11.9)	10.6 (10.0–11.1)	11.4 (11.2–11.6)
Digestive	10.6 (10.3–10.9)	10.4 (10.0–10.7)	11.1 (10.7–11.5)	10.6 (10.2–11.0)	10.4 (10.0–10.8)	10.4 (10.3–10.5)
Psychological	7.6 (7.2–8.0)	7.2 (6.8–7.6)	8.1 (7.7–8.6)	7.8 (7.3–8.3)	7.3 (6.9–7.8)	8.0 (7.8–8.2)
Endocrine & metabolic	5.6 (5.3–5.9)	5.4 (5.1–5.7)	6.2 (5.9–6.5)	6.4 (6.1–6.7)	6.0 (5.7–6.3)	6.0 (5.8–6.1)
Female genital system	5.3 (5.0–5.7)	5.3 (4.9–5.7)	5.5 (5.1–5.9)	5.5 (5.1–5.9)	6.1 (5.7–6.6)	6.4 (6.2–6.6)
Neurological	5.3 (5.1–5.5)	5.6 (5.4–5.8)	5.8 (5.5–6.0)	5.4 (5.2–5.6)	5.7 (5.5–6.0)	5.5 (5.4–5.6)
Ear	4.5 (4.3–4.7)	4.2 (4.0–4.4)	4.2 (4.0–4.3)	4.2 (4.0–4.4)	4.0 (3.8–4.1)	4.1 (4.0–4.2)
Pregnancy & family planning	3.4 (3.4–4.0)	3.8 (3.5–4.2)	3.5 (3.2–3.8)	3.5 (3.2–3.8)	3.6 (3.3–3.9)	3.9 (3.7–4.0)
Eye	2.7 (2.7–3.0)	2.8 (2.7–3.0)	2.7 (2.5–2.8)	2.5 (2.4–2.7)	2.7 (2.6–2.9)	2.7 (2.6–2.7)
Urology	2.5 (2.3–2.6)	2.6 (2.5–2.8)	2.4 (2.3–2.6)	2.5 (2.4–2.7)	2.5 (2.3–2.6)	2.5 (2.5–2.6)
Blood	1.8 (1.6–2.0)	2.1 (1.9–2.3)	2.0 (1.8–2.2)	1.1 (0.9–1.2)	1.0 (0.8–1.2)	1.6 (1.5–1.6)
Male genital system	1.1 (0.9–1.2)	1.0 (0.9–1.1)	1.1 (1.0–1.3)	1.0 (0.9–1.1)	1.0 (0.9–1.2)	1.0 (1.0–1.1)
Social problems	0.9 (0.7–1.1)	1.0 (0.8–1.1)	0.9 (0.7–1.1)	1.0 (0.8–1.1)	1.0 (0.8–1.2)	1.1 (1.0–1.1)
Total RFEs	146.3 (144.6–148.0)	148.5 (146.7–150.2)	151.0 (149.2–152.8)	149.2 (147.4–150.9)	150.9 (149.0–152.7)	150.2 (149.5–150.8)

(a) Figures do not total 100% as more than one RFEs can be recorded for each encounter.

Note: CI—confidence interval.

Table A4.6: Rate of RFEs by ICPC-2 component, summary of annual results BEACH 1998-99 to BEACH 2002-03

ICPC-2 component	1998-99	1999-00	2000-01	2001-02	2002-03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=753,925)
Symptoms & complaints	71.1 (69.4-72.9)	73.4 (71.5-75.3)	76.6 (74.6-78.6)	74.1 (72.3-75.9)	74.0 (72.0-76.1)	72.5 (71.8-73.1)
Diagnosis, diseases	33.6 (31.9-35.2)	27.7 (26.2-29.2)	29.0 (27.6-30.5)	27.3 (25.9-28.7)	26.0 (24.6-27.4)	28.5 (28.0-29.1)
Diagnostic & preventive procedures	22.4 (21.5-23.3)	22.9 (22.0-23.8)	22.3 (21.4-23.2)	22.7 (21.7-23.6)	23.8 (22.8-24.7)	24.1 (23.7-24.5)
Medications, treatments & therapeutics	10.3 (9.8-10.9)	12.0 (11.4-12.6)	11.2 (10.6-11.8)	11.9 (11.3-12.4)	13.0 (12.4-13.6)	12.2 (11.9-12.4)
Referral & other RFEs	4.4 (4.0-4.7)	7.2 (6.7-7.7)	6.5 (6.0-7.0)	7.2 (6.7-7.7)	7.0 (6.6-7.5)	6.9 (6.7-7.1)
Results	3.4 (3.1-3.7)	4.0 (3.7-4.3)	4.2 (3.9-4.6)	4.7 (4.4-5.1)	5.4 (5.0-5.7)	4.6 (4.4-4.7)
Administrative	1.1 (0.9-1.2)	1.3 (1.1-1.4)	1.1 (0.9-1.3)	1.3 (1.1-1.5)	1.6 (1.4-1.8)	1.4 (1.3-1.4)
Total RFEs	146.3 (144.6-148.0)	148.5 (146.7-150.2)	151.0 (149.2-152.8)	149.2 (147.4-150.9)	150.9 (149.0-152.7)	150.2 (149.5-150.8)

(a) Figures do not total 100% as more than one RFEs can be recorded for each encounter.

Note: CI—confidence interval.

Table A4.7: Distribution of problems managed, summary of annual results BEACH 1998–99 to BEACH 2002–03

Problem managed	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=502,100)
Respiratory	24.3 (23.6–25.0)	24.2 (23.5–24.9)	22.5 (21.9–23.2)	21.4 (20.7–22.0)	20.6 (20.0–21.3)	21.7 (21.4–21.9)
Musculoskeletal	16.9 (16.3–17.5)	16.9 (16.4–17.4)	17.4 (16.9–18.0)	17.5 (17.0–18.0)	17.1 (16.5–17.6)	17.4 (17.1–17.6)
Skin	16.5 (16.0–17.0)	17.0 (16.6–17.5)	16.7 (16.2–17.3)	16.1 (15.6–16.6)	16.5 (16.0–17.0)	16.6 (16.4–16.8)
Circulatory	16.1 (15.4–16.8)	16.3 (15.5–17.0)	16.0 (15.3–16.7)	16.1 (15.5–16.8)	16.0 (15.3–16.7)	16.6 (16.3–16.9)
General & unspecified	13.2 (12.7–13.7)	13.9 (13.4–14.5)	14.2 (13.7–14.7)	14.7 (14.0–15.5)	15.8 (15.2–16.3)	15.0 (14.8–15.3)
Psychological	10.5 (10.0–11.0)	10.5 (10.0–11.1)	10.8 (10.2–11.3)	10.6 (10.1–11.2)	10.3 (9.8–10.8)	11.3 (11.1–11.6)
Digestive	10.2 (9.9–10.5)	10.1 (9.7–10.3)	9.9 (9.6–10.2)	9.9 (9.6–10.2)	10.1 (9.8–10.4)	10.0 (9.9–10.2)
Endocrine & metabolic	8.8 (8.4–9.2)	9.1 (8.7–9.6)	9.8 (9.3–10.2)	10.4 (10.0–10.9)	10.6 (10.2–11.0)	9.9 (9.8–10.1)
Female genital system	6.3 (5.9–6.6)	6.2 (5.8–6.6)	6.1 (5.7–6.4)	6.1 (5.8–6.5)	6.7 (6.2–7.1)	7.3 (7.1–7.5)
Ear	4.9 (4.7–5.1)	4.5 (4.3–4.7)	4.4 (4.2–4.6)	4.2 (4.0–4.4)	4.0 (3.8–4.2)	4.3 (4.2–4.4)
Pregnancy & family planning	4.1 (3.7–4.4)	4.3 (4.0–4.6)	3.9 (3.6–4.2)	4.0 (3.7–4.3)	4.2 (3.8–4.5)	4.3 (4.2–4.5)
Neurological	4.0 (3.8–4.2)	3.9 (3.7–4.1)	3.8 (3.6–3.9)	3.7 (3.5–3.9)	4.2 (4.0–4.4)	4.0 (3.9–4.1)
Urology	2.8 (2.7–3.0)	3.0 (2.9–3.2)	2.7 (2.5–2.8)	2.8 (2.7–3.0)	2.8 (2.7–3.0)	3.0 (2.9–3.0)
Eye	2.8 (2.7–3.0)	2.7 (2.6–2.9)	2.6 (2.5–2.7)	2.5 (2.4–2.6)	2.6 (2.5–2.7)	2.7 (2.6–2.7)
Blood	1.7 (1.5–1.9)	1.7 (1.5–1.9)	1.7 (1.5–1.8)	1.3 (1.2–1.4)	1.4 (1.2–1.5)	1.6 (1.5–1.7)
Male genital system	1.4 (1.3–1.5)	1.4 (1.3–1.5)	1.5 (1.3–1.6)	1.3 (1.1–1.4)	1.4 (1.3–1.6)	1.4 (1.3–1.4)
Social problems	0.8 (0.6–0.9)	0.9 (0.7–1.1)	0.7 (0.5–0.9)	0.7 (0.5–0.9)	0.7 (0.5–0.9)	0.9 (0.9–1.0)
Total problems	145.3 (143.5–147.2)	146.7 (144.9–148.6)	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	148.1 (147.3–148.9)

(a) Figures do not total 100% as more than one problem can be managed at each encounter.

Note: CI—confidence interval.

Table A4.8: Most frequently managed problems, summary of annual results BEACH 1998–99 to BEACH 2002–03

Problem managed	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n= 100,987)	Rate per 100 encounters ^(a) (95% CI) (n=502,100)
Hypertension*	8.3 (7.8–8.7)	8.4 (7.9–8.9)	8.6 (8.2–9.1)	9.0 (8.6–9.5)	8.9 (8.4–9.3)	8.8 (8.6–9.0)
Upper respiratory tract infection	6.8 (6.4–7.3)	7.2 (6.7–7.7)	6.9 (6.5–7.4)	6.2 (5.8–6.6)	6.4 (5.9–6.8)	6.0 (5.9–6.2)
Immunisation/vaccination—all*	5.2 (4.7–5.7)	4.6 (4.2–5.0)	4.6 (4.2–5.0)	4.7 (4.2–5.1)	4.6 (4.2–5.1)	4.8 (4.6–5.0)
Depression*	3.5 (3.3–3.7)	3.4 (3.2–3.6)	3.7 (3.4–3.9)	3.4 (3.2–3.6)	3.5 (3.3–3.8)	3.8 (3.7–3.9)
Acute bronchitis/bronchiolitis	3.3 (3.0–3.6)	3.2 (2.9–3.4)	2.7 (2.5–3.0)	2.7 (2.5–3.0)	2.6 (2.3–2.8)	2.8 (2.7–2.8)
Asthma	3.2 (3.0–3.4)	3.2 (3.0–3.4)	2.8 (2.7–3.0)	2.8 (2.6–3.0)	2.7 (2.5–2.9)	2.9 (2.8–3.0)
Back complaint*	2.7 (2.4–2.9)	2.8 (2.6–2.9)	2.6 (2.4–2.8)	2.6 (2.4–2.8)	2.6 (2.3–2.8)	2.6 (2.5–2.7)
Diabetes*	2.6 (2.4–2.7)	2.7 (2.5–2.9)	2.8 (2.6–3.0)	3.1 (2.9–3.3)	2.9 (2.7–3.1)	2.8 (2.7–2.9)
Lipid disorder	2.5 (2.3–2.7)	2.6 (2.4–2.9)	2.9 (2.7–3.1)	2.9 (2.7–3.1)	3.0 (2.8–3.2)	2.8 (2.7–2.9)
Osteoarthritis*	2.2 (2.0–2.4)	2.2 (2.0–2.4)	2.5 (2.3–2.7)	2.6 (2.4–2.8)	2.6 (2.4–2.8)	2.4 (2.4–2.5)
Total problems	145.3 (143.5–147.2)	146.7 (144.9–148.6)	144.5 (142.8–146.3)	143.4 (141.7–145.2)	144.9 (143.0–146.8)	148.1 (147.3–148.9)

(a) Figures do not total 100% as more than one problem can be managed at each encounter. Also only the most frequent problems are included.

* Includes multiple ICPC–2 or ICPC–2 PLUS codes (see Appendix 3).

Note: CI—confidence interval.

Table A4.9: Distribution of medications prescribed by group and subgroup, summary of annual results BEACH 1998–99 to BEACH 2002–03

Group and subgroup	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=502,100)
Antibiotics	17.3 (16.7–18.0)	16.3 (15.8–16.9)	15.9 (15.3–16.5)	14.4 (13.9–14.9)	13.8 (13.2–14.4)	14.9 (14.6–15.1)
Broad-spectrum penicillin	5.0 (4.7–5.4)	4.7 (4.4–5.1)	4.9 (4.6–5.2)	4.5 (4.2–4.8)	4.7 (4.4–5.1)	5.1 (5.0–5.3)
Cephalosporins	4.3 (4.0–4.7)	4.0 (3.7–4.4)	4.0 (3.6–4.3)	3.2 (3.0–3.5)	3.0 (2.8–3.2)	2.7 (2.6–2.8)
Other antibiotics	3.5 (3.2–3.7)	3.4 (3.2–3.7)	3.3 (3.1–3.6)	3.0 (2.8–3.2)	2.8 (2.6–3.0)	3.2 (3.1–3.3)
Penicillins	1.5 (1.3–1.7)	1.5 (1.3–1.7)	1.3 (1.1–1.4)	1.5 (1.2–1.7)	1.2 (1.0–1.4)	1.4 (1.3–1.4)
Tetracycline	1.4 (1.2–1.6)	1.1 (1.0–1.3)	1.1 (1.0–1.3)	1.0 (0.8–1.2)	0.9 (0.7–1.0)	1.1 (1.0–1.2)
Cardiovascular	13.7 (12.9–14.5)	13.7 (12.9–14.5)	13.6 (12.8–14.4)	13.9 (13.2–14.7)	13.1 (12.3–13.9)	13.7 (13.3–14.0)
Anti-hypertensives	7.2 (6.8–7.6)	7.1 (6.7–7.6)	7.3 (6.9–7.7)	7.5 (7.1–8.0)	7.3 (6.8–7.8)	7.3 (7.2–7.5)
Other cardiovascular drugs	2.1 (1.9–2.3)	2.4 (2.2–2.8)	2.6 (2.4–2.8)	2.7 (2.5–2.9)	2.6 (2.4–2.8)	2.5 (2.4–2.5)
Anti-angina	1.5 (1.3–1.7)	1.3 (1.1–1.5)	1.1 (0.9–1.3)	1.1 (0.9–1.3)	0.8 (0.6–1.1)	1.2 (1.1–1.2)
Beta-blockers	1.7 (1.6–1.9)	1.8 (1.6–2.0)	1.6 (1.4–1.8)	1.7 (1.5–1.9)	1.5 (1.3–1.7)	1.7 (1.6–1.8)
Central nervous system	11.4 (10.8–11.9)	11.6 (11.0–12.2)	11.1 (10.5–11.7)	10.7 (10.1–11.2)	10.5 (10.0–11.1)	10.7 (10.5–10.9)
Simple analgesics	4.7 (4.4–5.1)	5.0 (4.6–5.4)	4.8 (4.3–5.2)	3.8 (3.4–4.1)	3.9 (3.4–4.3)	4.2 (4.0–4.3)
Compound analgesics	3.3 (3.1–3.6)	3.0 (2.8–3.2)	2.7 (2.5–2.9)	2.7 (2.5–2.9)	2.4 (2.2–2.6)	2.7 (2.6–2.8)
Narcotic analgesics	1.1 (0.6–1.6)	1.3 (0.9–1.8)	1.4 (1.0–1.8)	2.0 (1.6–2.4)	2.2 (1.9–2.6)	1.7 (1.5–1.8)
Anti-emetic/anti-nausea	1.4 (1.3–1.6)	1.6 (1.5–1.7)	1.5 (1.3–1.6)	1.4 (1.2–1.5)	1.3 (1.2–1.5)	1.4 (1.3–1.5)
Psychological	7.6 (7.2–7.9)	7.5 (7.1–8.0)	7.5 (7.1–7.9)	7.4 (7.0–7.8)	7.0 (6.6–7.4)	7.6 (7.5–7.8)
Sedative hypnotics	2.0 (1.8–2.2)	1.9 (1.7–2.1)	1.9 (1.7–2.1)	1.9 (1.7–2.2)	1.7 (1.6–1.9)	1.9 (1.9–2.0)
Anti anxiety	2.1 (1.9–2.3)	2.1 (1.9–2.3)	2.0 (1.8–2.2)	1.9 (1.7–2.2)	1.9 (1.7–2.1)	2.0 (1.9–2.1)
Anti-depressants	2.9 (2.7–3.1)	2.9 (2.8–3.1)	3.1 (2.8–3.3)	2.9 (2.7–3.1)	2.9 (2.7–3.1)	3.1 (3.0–3.2)

(continued)

Table A4.9 (continued): Distribution of medications prescribed by group and subgroup, summary of annual results BEACH 1998–99 to BEACH 2002–03

Group and subgroup	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=502,100)
Respiratory	6.9 (6.5–7.3)	7.4 (6.9–7.9)	6.3 (5.9–6.7)	5.8 (5.3–6.2)	5.3 (4.9–5.7)	6.0 (5.9–6.2)
Bronchodilators	3.7 (3.5–4.0)	3.8 (3.5–4.1)	3.2 (2.9–3.4)	2.9 (2.6–3.1)	2.5 (2.2–2.7)	3.0 (2.9–3.1)
Asthma preventives	2.2 (2.1–2.4)	2.5 (2.3–2.8)	2.2 (2.0–2.4)	2.2 (2.0–2.4)	2.0 (1.9–2.2)	2.2 (2.1–2.3)
Hormones	5.8 (5.5–6.1)	5.9 (5.5–6.2)	5.9 (5.6–6.2)	6.1 (5.8–6.4)	5.4 (5.1–5.7)	6.0 (5.9–6.1)
Sex hormones	2.2 (2.0–2.4)	2.1 (1.9–2.2)	2.1 (1.9–2.2)	2.0 (1.8–2.1)	1.8 (1.6–1.9)	2.2 (2.1–2.3)
Cortico steroids	1.2 (1.1–1.4)	1.4 (1.2–1.6)	1.2 (1.1–1.4)	1.3 (1.2–1.5)	1.1 (0.9–1.2)	1.3 (1.2–1.3)
Hypoglycaemics	1.8 (1.5–2.0)	1.8 (1.5–2.1)	2.0 (1.7–2.3)	2.2 (1.9–2.5)	1.9 (1.6–2.2)	1.9 (1.8–2.0)
Other hormones	0.6 (0.4–0.7)	0.6 (0.4–0.7)	0.6 (0.5–0.7)	0.6 (0.5–0.8)	0.6 (0.5–0.8)	0.6 (0.6–0.7)
Musculoskeletal	5.7 (5.4–6.0)	5.7 (5.4–6.0)	6.8 (6.4–7.1)	6.1 (5.8–6.4)	5.7 (5.4–6.0)	5.8 (5.7–5.9)
NSAID/anti-rheumatoid	4.5 (4.2–4.7)	4.6 (4.3–4.8)	5.7 (5.4–6.0)	5.3 (5.0–5.5)	4.8 (4.5–5.0)	4.8 (4.7–4.9)
Allergy, immune system	4.8 (4.3–5.4)	5.2 (4.8–5.6)	4.6 (4.2–5.0)	4.5 (4.1–4.8)	4.8 (4.3–5.3)	4.8 (4.6–4.9)
Anti-histamine	0.8 (0.5–1.1)	0.7 (0.5–0.9)	0.6 (0.4–0.8)	0.4 (0.2–0.7)	0.5 (0.0–1.0)	0.6 (0.5–0.6)
Vaccines	3.9 (3.3–4.6)	4.4 (3.9–4.8)	3.9 (3.4–4.3)	3.9 (3.5–4.3)	4.2 (3.7–4.7)	4.1 (3.9–4.3)
Skin	4.5 (4.2–4.7)	4.6 (4.4–4.8)	4.8 (4.5–5.2)	4.1 (3.9–4.4)	3.9 (3.7–4.2)	4.3 (4.2–4.4)
Anti-infection, skin	1.0 (0.8–1.1)	1.0 (0.8–1.1)	0.9 (0.7–1.1)	0.7 (0.5–0.8)	0.7 (0.5–0.8)	0.8 (0.8–0.9)
Topical steroids	2.8 (2.7–3.0)	2.8 (2.7–3.0)	3.1 (2.8–3.3)	2.8 (2.6–3.0)	2.6 (2.5–2.8)	2.7 (2.7–2.8)
Other skin	0.6 (0.5–0.8)	0.8 (0.6–0.9)	0.9 (0.6–1.1)	0.6 (0.4–0.8)	0.6 (0.4–0.8)	0.7 (0.6–0.8)
Digestive	4.3 (4.1–4.5)	4.3 (4.1–4.5)	4.1 (3.8–4.3)	3.8 (3.6–4.1)	3.9 (3.6–4.1)	4.0 (3.9–4.1)
Anti-spasmodics	0.5 (0.3–0.6)	0.4 (0.3–0.6)	0.3 (0.1–0.5)	0.2 (0.0–0.4)	0.2 (0.0–0.4)	0.3 (0.3–0.4)
Anti-ulcerants	2.2 (2.1–2.4)	2.2 (2.0–2.4)	2.2 (2.0–2.3)	2.4 (2.2–2.5)	2.4 (2.2–2.6)	2.2 (2.2–2.3)
Antidiarrhoeals	0.6 (0.5–0.8)	0.5 (0.4–0.7)	0.5 (0.3–0.8)	0.5 (0.3–0.7)	0.5 (0.3–0.7)	0.5 (0.4–0.6)

(continued)

Table A4.9 (continued): Distribution of medications prescribed by group and subgroup, summary of annual results BEACH 1998–99 to BEACH 2002–03

Group and subgroup	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=502,100)
Urogenital	2.2 (2.0–2.4)	2.0 (1.8–2.2)	1.8 (1.7–2.0)	1.8 (1.6–2.0)	1.7 (1.5–1.9)	2.1 (2.0–2.1)
Diuretics	1.7 (1.5–1.9)	1.5 (1.3–1.7)	1.3 (1.1–1.4)	1.3 (1.1–1.5)	1.1 (0.9–1.3)	1.5 (1.4–1.6)
Ear, nose topical	2.3 (2.1–2.5)	2.5 (2.3–2.6)	2.3 (2.2–2.5)	1.8 (1.7–2.0)	1.6 (1.4–1.7)	2.0 (2.0–2.1)
Topical otic	1.0 (0.8–1.2)	1.0 (0.8–1.1)	1.0 (0.8–1.1)	0.9 (0.8–1.1)	0.9 (0.7–1.0)	0.9 (0.9–1.0)
Topical nasal	1.3 (1.1–1.4)	1.5 (1.3–1.7)	1.3 (1.2–1.5)	0.9 (0.7–1.0)	0.7 (0.5–0.9)	1.1 (1.1–1.2)
Contraceptives	1.7 (1.5–1.8)	1.7 (1.6–1.9)	1.6 (1.5–1.8)	1.7 (1.5–1.8)	1.7 (1.5–1.9)	1.8 (1.7–1.9)
Oral/systemic contraception	1.7 (1.5–1.8)	1.7 (1.6–1.9)	1.6 (1.5–1.8)	1.7 (1.5–1.8)	1.7 (1.5–1.9)	1.8 (1.7–1.9)
Blood	1.6 (1.4–1.8)	1.6 (1.4–1.7)	1.8 (1.7–2.0)	1.8 (1.7–2.0)	1.7 (1.6–1.9)	1.8 (1.7–1.8)
Other blood	0.7 (0.6–0.9)	0.8 (0.6–0.9)	0.9 (0.7–1.1)	1.1 (0.9–1.3)	1.0 (0.9–1.2)	0.9 (0.8–1.0)
Eye medications	1.7 (1.5–1.8)	1.7 (1.6–1.8)	1.6 (1.5–1.8)	1.5 (1.4–1.6)	1.6 (1.5–1.8)	1.6 (1.5–1.6)
Anti-infectives	1.1 (1.0–1.2)	1.1 (1.0–1.2)	1.0 (0.9–1.2)	0.9 (0.8–1.1)	1.0 (0.9–1.2)	1.0 (0.9–1.0)
Nutrition, metabolism	1.2 (1.1–1.4)	1.1 (0.9–1.3)	1.4 (1.2–1.5)	1.7 (1.1–2.2)	1.6 (1.4–1.8)	1.5 (1.4–1.6)
Mineral tonic	0.7 (0.5–0.8)	0.6 (0.4–0.7)	0.5 (0.4–0.7)	0.6 (0.3–0.8)	0.5 (0.3–0.7)	0.6 (0.5–0.7)
Miscellaneous	0.5 (0.0–1.2)	0.4 (0.0–0.8)	0.6 (0.4–0.8)	0.5 (0.3–0.6)	0.3 (0.1–0.6)	0.5 (0.3–0.6)

(a) Column will not add to 100 because multiple prescriptions could be written at each encounter. Also only the most frequent medications are included.

Note: CI—confidence interval.

Table A4.10: Most frequently prescribed medications, summary of annual results BEACH 1998–99 to BEACH 2002–03

Generic drug	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n= 502,100)
Paracetamol	3.9 (3.6–4.3)	4.1 (3.7–4.4)	3.9 (3.5–4.4)	3.1 (2.7–3.4)	3.1 (2.7–3.6)	3.4 (3.2–3.5)
Amoxicillin	3.2 (2.9–3.5)	3.1 (2.8–3.4)	3.2 (2.9–3.5)	2.9 (2.7–3.2)	3.1 (2.8–3.5)	2.9 (2.8–3.0)
Paracetamol/codeine	2.7 (2.4–2.9)	2.4 (2.2–2.6)	2.2 (2.0–2.4)	2.2 (2.0–2.4)	2.0 (1.8–2.2)	2.2 (2.1–2.3)
Salbutamol	2.4 (2.2–2.6)	2.4 (2.2–2.6)	2.1 (1.9–2.3)	2.0 (1.8–2.2)	1.7 (1.5–1.9)	2.0 (1.9–2.0)
Cefaclor monohydrate	2.2 (1.8–2.6)	1.6 (1.3–2.0)	1.6 (1.3–2.0)	1.1 (0.8–1.3)	1.0 (0.7–1.3)	0.7 (0.5–0.9)
Cephalexin	2.1 (1.9–2.4)	2.1 (1.8–2.3)	2.2 (2.0–2.4)	2.0 (1.8–2.2)	1.9 (1.7–2.1)	1.9 (1.9–2.0)
Roxithromycin	1.8 (1.5–2.0)	1.8 (1.6–2.0)	1.6 (1.4–1.8)	1.4 (1.2–1.6)	1.3 (1.1–1.6)	1.6 (1.5–1.7)
Amoxicillin/potass. clavulanate	1.8 (1.5–2.0)	1.6 (1.4–1.8)	1.7 (1.4–1.9)	1.6 (1.3–1.8)	1.6 (1.4–1.8)	1.5 (1.5–1.6)
Influenza virus vaccine	1.7 (0.4–3.0)	1.5 (0.9–2.1)	1.5 (0.8–2.2)	1.5 (0.8–2.2)	1.4 (0.6–2.3)	1.5 (1.2–1.9)
Temazepam	1.4 (1.3–1.6)	1.4 (1.3–1.6)	1.4 (1.3–1.6)	1.3 (1.2–1.5)	1.2 (1.0–1.3)	1.4 (1.3–1.5)
Diclofenac sodium systemic	1.3 (1.1–1.5)	1.3 (1.1–1.5)	1.2 (0.9–1.4)	0.9 (0.7–1.1)	0.7 (0.5–0.9)	1.0 (0.9–1.1)
Levonorgestrel/ethinyloestradiol	1.2 (1.1–1.4)	1.3 (1.1–1.4)	1.2 (1.1–1.4)	1.2 (1.1–1.3)	1.1 (1.0–1.3)	1.3 (1.2–1.3)
Doxycycline hydrochloride	1.2 (1.0–1.3)	0.9 (0.7–1.1)	0.9 (0.7–1.1)	0.8 (0.6–1.0)	0.7 (0.5–0.9)	0.9 (0.8–1.0)
Diazepam	1.1 (0.9–1.3)	1.1 (0.9–1.3)	1.0 (0.9–1.2)	1.0 (0.8–1.3)	1.0 (0.8–1.2)	1.1 (1.0–1.2)
Erythromycin	1.1 (0.8–1.3)	0.7 (0.5–0.9)	0.8 (0.6–1.0)	0.6 (0.4–0.8)	0.5 (0.3–0.7)	0.7 (0.6–0.8)
Ranitidine	1.0 (0.9–1.1)	1.0 (0.8–1.1)	1.0 (0.9–1.2)	0.6 (0.5–0.8)	0.5 (0.3–0.6)	1.8 (0.8–0.9)
Atenolol	1.0 (0.8–1.1)	1.0 (0.8–1.2)	0.9 (0.7–1.1)	1.0 (0.7–1.2)	0.8 (0.6–1.0)	0.9 (0.9–1.0)
Frusamide (furosemide)	1.0 (0.8–1.1)	0.8 (0.6–1.0)	0.7 (0.7–0.9)	0.7 (0.5–0.9)	0.7 (0.5–0.9)	0.8 (0.7–0.9)
Betamethasone topical	0.9 (0.8–1.1)	0.9 (0.7–1.0)	1.0 (0.9–1.2)	0.9 (0.7–1.0)	0.7 (0.6–0.9)	0.9 (0.8–0.9)
Simvastatin	0.9 (0.8–1.1)	0.9 (0.7–1.1)	0.9 (0.7–1.1)	0.9 (0.8–1.1)	0.9 (0.7–1.0)	0.9 (0.8–1.0)
Chloramphenicol eye	0.9 (0.8–1.1)	0.9 (0.8–1.0)	0.9 (0.7–1.0)	0.8 (0.7–0.9)	0.9 (0.8–1.1)	0.8 (0.8–0.9)
Metformin	0.7 (0.5–0.9)	0.7 (0.5–0.9)	0.8 (0.6–1.0)	0.9 (0.8–1.1)	0.8 (0.7–1.0)	0.8 (0.7–0.8)
Atorvastatin	0.6 (0.4–0.8)	0.8 (0.6–0.9)	0.9 (0.8–1.0)	1.0 (0.9–1.2)	1.0 (0.9–1.2)	0.9 (0.8–1.0)

(continued)

Table A4.10 (continued): Most frequently prescribed medications, summary of annual results BEACH 1998–99 to BEACH 2002–03

Generic drug	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=502,100)
Omeprazole	0.5 (0.3–0.6)	0.4 (0.3–0.6)	0.5 (0.3–0.6)	0.8 (0.7–1.0)	0.8 (0.7–1.0)	0.8 (0.8–0.9)
Irbesartan	0.5 (0.3–0.8)	0.7 (0.5–0.9)	0.8 (0.6–0.9)	0.8 (0.6–0.9)	0.8 (0.7–1.0)	0.7 (0.6–0.8)
Tramadol	0.0 (0.0–0.0)	0.1 (0.0–1.1)	0.2 (0.0–0.5)	0.7 (0.4–0.9)	1.0 (0.8–1.1)	0.3 (0.2–0.5)
Celecoxib	..	0.2 (0.0–0.6)	2.1 (1.9–2.4)	1.4 (1.3–1.6)	1.1 (0.9–1.2)	1.0 (0.9–1.1)
Rofecoxib	0.1 (0.0–0.8)	1.2 (1.0–1.5)	1.2 (0.9–1.4)	0.5 (0.3–0.6)
Fluticasone/salmeterol	0.2 (0.0–0.6)	0.6 (0.4–0.8)	0.9 (0.7–1.1)	0.3 (0.2–0.4)
Total prescribed medications	93.6 (91.2–96.1)	93.8 (91.5–96.2)	92.3 (89.9–94.7)	88.0 (85.6–90.4)	84.3 (81.8–86.9)	89.4 (88.4–90.4)

(a) Column will not add to 100 because multiple prescriptions could be written at each encounter.

Note: CI—confidence interval.

Table A4.11: Distribution of medications prescribed by ATC medication group, summary of annual results BEACH 1998–99 to BEACH 2002–03

ATC medication group	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters (95% CI) (n=96,901)	Rate per 100 encounters (95% CI) (n=104,856)	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=502,100)
Other analgesics & antipyretics	7.7 (7.2–8.1)	7.5 (7.1–8.0)	7.1 (6.6–7.6)	6.1 (5.7–6.5)	6.0 (5.5–6.5)	6.5 (6.4–6.7)
Beta-lactam antibacterials, penicillins	6.2 (5.8–6.5)	6.2 (5.8–6.6)	6.1 (5.8–6.5)	6.0 (5.6–6.3)	5.9 (5.5–6.3)	5.7 (5.6–5.9)
Antiinflammatory/antirheumatic non-steroid	4.5 (4.2–4.7)	4.5 (4.3–4.8)	5.7 (5.4–6.0)	5.3 (5.0–5.5)	4.8 (4.5–5.0)	4.8 (4.7–4.9)
Other beta-lactam antibacterials	4.3 (4.0–4.7)	4.0 (3.7–4.4)	4.0 (3.6–4.3)	3.2 (3.0–3.5)	3.0 (2.8–3.2)	3.4 (3.3–3.5)
ACE inhibitors, plain	3.4 (3.2–3.7)	3.3 (3.1–3.5)	2.9 (2.7–3.1)	2.8 (2.6–3.0)	2.5 (2.3–2.7)	3.0 (2.9–3.1)
Adrenergics inhalants	3.2 (3.0–3.5)	3.3 (3.1–3.6)	3.1 (2.9–3.3)	3.2 (2.9–3.4)	3.0 (2.8–3.3)	3.0 (2.9–3.1)
Macrolides /lincosamides/streptogramins	2.9 (2.7–3.2)	2.8 (2.6–3.0)	2.8 (2.5–3.0)	2.4 (2.2–2.6)	2.3 (2.0–2.5)	2.6 (2.5–2.6)
Anti-depressants	2.9 (2.7–3.1)	2.9 (2.8–3.1)	3.1 (2.8–3.3)	3.1 (2.9–3.3)	2.9 (2.7–3.1)	3.1 (3.0–3.2)
Other inhalants for obstructive airway diseases	2.8 (2.6–3.0)	3.0 (2.8–3.3)	2.3 (2.1–2.5)	1.9 (1.7–2.1)	3.0 (2.8–3.3)	2.3 (2.2–2.3)
Viral vaccines	2.6 (1.9–3.3)	2.6 (2.2–3.0)	2.6 (2.2–3.0)	2.6 (2.2–3.0)	2.4 (2.0–2.9)	2.6 (2.4–2.7)
Corticosteroids plain	2.2 (2.1–2.4)	2.3 (2.1–2.4)	2.6 (2.4–2.9)	2.4 (2.2–2.6)	2.2 (2.0–2.3)	2.2 (2.2–2.3)
Drugs for peptic ulcer and GORD	2.2 (2.1–2.4)	2.2 (2.0–2.4)	2.2 (2.0–2.3)	2.4 (2.2–2.5)	2.4 (2.2–2.6)	2.2 (2.2–2.3)
Anxiolytics	2.1 (1.9–2.3)	2.1 (1.9–2.3)	2.0 (1.8–2.2)	1.9 (1.7–2.2)	1.9 (1.7–2.1)	2.0 (1.9–2.1)
Hypnotics & sedatives	1.9 (1.8–2.2)	1.9 (1.7–2.1)	1.9 (1.7–2.1)	1.9 (1.7–2.1)	1.7 (1.5–1.9)	1.9 (1.8–2.0)
Cholesterol & triglyceride reducers	1.9 (1.7–2.1)	2.2 (2.0–2.4)	2.4 (2.2–2.5)	2.4 (2.3–2.6)	2.4 (2.2–2.6)	2.2 (2.2–2.3)
Beta-blocking agents plain	1.8 (1.6–2.0)	1.9 (1.7–2.1)	1.7 (1.5–1.9)	1.8 (1.6–2.1)	1.6 (1.4–1.8)	1.8 (1.7–1.8)
Hormonal contraceptives for systemic use	1.8 (1.6–1.9)	1.9 (1.7–2.0)	1.8 (1.7–2.0)	1.9 (1.7–2.0)	1.9 (1.7–2.1)	2.0 (1.9–2.1)
Selective calcium channel blockers with mainly vascular effects	1.8 (1.6–1.9)	1.6 (1.4–1.8)	1.6 (1.4–1.8)	1.5 (1.3–1.7)	1.3 (1.1–1.5)	1.6 (1.5–1.6)
Opioids	1.5 (1.1–1.9)	1.7 (1.3–2.1)	1.4 (1.2–1.6)	2.1 (1.8–2.3)	2.2 (2.0–2.5)	1.8 (1.7–2.0)
Oral blood glucose lowering drugs	1.5 (1.2–1.7)	1.5 (1.2–1.7)	1.7 (1.4–1.9)	1.9 (1.6–2.1)	1.6 (1.3–1.8)	1.5 (1.4–1.6)
Total prescribed medications	93.6 (91.2–96.1)	93.8 (91.5–96.2)	92.3 (89.9–94.7)	88.0 (85.6–90.4)	84.3 (81.8–86.9)	89.4 (88.4–90.4)

Note: CI—confidence interval.

Table A4.12: Most frequently advised over-the-counter medications, summary of annual results BEACH 1998–99 to BEACH 2001–02

	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters (95% CI) (n=104,856)	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=502,100)
Generic medication						
Paracetamol	2.4 (1.8–2.9)	2.5 (2.0–3.0)	2.4 (1.8–2.9)	2.1 (1.7–2.6)	2.6 (2.1–3.0)	2.2 (2.1–2.4)
Chlorpheniramine/phenylephrine	0.3 (0.0–0.7)	0.3 (0.0–0.7)	0.1 (0.0–0.5)	0.1 (0.0–0.4)	0.1 (0.0–0.7)	0.1 (0.0–0.3)
Clotrimazole topical	0.2 (0.0–0.4)	0.2 (0.0–0.4)	0.2 (0.0–0.5)	0.2 (0.0–0.4)	0.2 (0.0–0.4)	0.2 (0.1–0.3)
Paracetamol/Codeine	0.2 (0.0–0.6)	0.3 (0.0–0.8)	0.2 (0.0–0.5)	0.2 (0.0–0.5)	0.1 (0.0–0.5)	0.2 (0.1–0.4)
Ibuprofen	0.2 (0.0–0.5)	0.3 (0.0–0.7)	0.5 (0.2–0.8)	0.5 (0.2–0.8)	0.7 (0.1–1.3)	0.4 (0.3–0.5)
Loratadine	0.2 (0.0–0.5)	0.3 (0.0–0.6)	0.2 (0.0–0.6)	0.3 (0.0–0.5)	0.3 (0.0–0.6)	0.2 (0.1–0.4)
Diclofenac diethyl topical	0.2 (0.0–0.5)	0.2 (0.0–0.5)	0.2 (0.0–0.6)	0.2 (0.0–0.5)	0.2 (0.0–0.5)	0.2 (0.1–0.3)
Aspirin	0.2 (0.0–0.4)	0.2 (0.0–0.6)	0.1 (0.0–0.5)	0.2 (0.0–0.5)	0.2 (0.0–0.4)	0.2 (0.1–0.3)
Pseudoephedrine	0.2 (0.0–0.5)	0.2 (0.0–0.6)	0.2 (0.0–0.6)	0.1 (0.0–0.5)	0.1 (0.0–0.6)	0.1 (0.0–0.3)
Total advised medications	8.8 (8.0–9.6)	9.4 (8.6–10.2)	9.0 (8.1–9.8)	8.9 (8.1–9.6)	10.2 (9.2–11.1)	9.0 (8.8–9.3)

(a) Only those medications supplied at a rate of 0.2 per 100 encounters or more in 1998–99 are included.

Note: CI—confidence interval.

Table A4.13: Medications most frequently supplied by GPs, summary of annual results BEACH 1998–99 to BEACH 2001–02

	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters (95% CI) (n=104,856)	Rate per 100 encounters (95% CI) (n=99,307)	Rate per 100 encounters (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters (95% CI) (n=502,100)
Generic medication						
Influenza virus vaccine	0.8 (0.0–2.2)	0.7 (0.0–1.7)	0.6 (0.0–1.4)	0.9 (0.0–2.1)	0.7 (0.0–0.9)	0.8 (0.3–1.3)
Triple antigen(diphtheria/pertussis/tetanus)	0.4 (0.1–0.7)	0.3 (0.1–0.6)	0.2 (0.0–0.7)	0.2 (0.0–0.6)	0.1 (0.0–0.6)	0.3 (0.1–0.4)
Polio vaccine oral sabin/injection	0.4 (0.1–0.6)	0.4 (0.1–0.7)	0.3 (0.0–0.6)	0.3 (0.0–0.7)	0.3 (0.0–0.7)	0.3 (0.2–0.5)
Haemophilus B vaccine	0.3 (0.0–0.6)	0.3 (0.1–0.6)	0.2 (0.0–0.6)	0.2 (0.0–0.5)	0.2 (0.0–0.6)	0.2 (0.1–0.4)
Mumps/Measles/Rubella vaccine	0.2 (0.0–0.5)	0.2 (0.0–0.5)	0.2 (0.0–0.5)	0.2 (0.0–0.5)	0.1 (0.0–0.4)	0.2 (0.0–0.3)
ADT/CDT (diphtheria/tetanus) vaccine	0.2 (0.0–0.6)	0.3 (0.0–0.5)	0.2 (0.0–0.4)	0.1 (0.0–0.5)	0.1 (0.0–0.5)	0.2 (0.1–0.3)
Hepatitis B vaccine	0.2 (0.0–0.6)	0.2 (0.0–0.6)	0.2 (0.0–0.5)	0.1 (0.0–0.5)	0.1 (0.0–0.4)	0.2 (0.0–0.3)
Celecoxib	0.3 (0.0–0.7)	0.2 (0.0–0.5)	0.1 (0.0–0.5)	0.1 (0.0–0.3)
Rofecoxib	0.3 (0.0–0.5)	0.2 (0.0–0.6)	0.1 (0.0–0.3)
Total GP supplied medications	8.8 (8.0–9.6)	6.9 (5.8–7.9)	6.9 (5.7–8.1)	7.6 (6.3–9.0)	9.3 (7.6–11.0)	8.1 (7.7–8.6)

(a) Only those medications supplied at a rate of 0.2 per 100 encounters or more in 1998–99 are included with the exception of celecoxib and rofecoxib which are reported for years after acceptance on the PBS.

Note: CI—confidence interval.

Table A4.14: The ten most common problems managed with a clinical treatment, summary of annual results BEACH 1998–99 to BEACH 2002–03

Problem managed	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Rate per 100 encounters ^(a) (95% CI) (n=96,901)	Rate per 100 encounters ^(a) (95% CI) (n=104,856)	Rate per 100 encounters ^(a) (95% CI) (n=99,307)	Rate per 100 encounters ^(a) (95% CI) (n=96,973)	Rate per 100 encounters ^(a) (95% CI) (n=100,987)	Rate per 100 encounters ^(a) (95% CI) (n=502,100)
Depression*	1.6 (1.4–1.8)	1.6 (1.4–1.8)	1.8 (1.6–2.1)	1.7 (1.5–1.9)	1.7 (1.5–2.0)	1.9 (1.8–2.0)
URTI	1.2 (0.9–1.6)	1.4 (1.1–1.7)	1.7 (1.4–2.1)	2.0 (1.6–2.4)	1.8 (1.5–2.2)	1.5 (1.5–1.6)
Hypertension*	0.9 (0.7–1.1)	1.1 (0.8–1.3)	1.4 (1.0–1.8)	1.4 (1.1–1.6)	1.5 (1.1–1.9)	1.3 (1.2–1.3)
Anxiety*	0.8 (0.6–0.9)	0.8 (0.6–1.0)	0.8 (0.6–1.0)	0.8 (0.7–1.0)	0.7 (0.5–0.9)	0.8 (0.8–0.9)
Lipid disorder	0.7 (0.5–0.9)	0.8 (0.6–1.0)	1.0 (0.8–1.3)	1.0 (0.8–1.2)	0.9 (0.7–1.1)	0.9 (0.8–0.9)
Diabetes*	0.7 (0.5–0.9)	0.8 (0.6–1.0)	0.9 (0.7–1.1)	1.0 (0.8–1.2)	0.8 (0.7–1.0)	0.8 (0.8–0.9)
Gastroenteritis, presumed infection	0.6 (0.3–0.8)	0.5 (0.3–0.8)	0.6 (0.3–0.9)	0.6 (0.4–0.8)	0.6 (0.4–0.8)	0.5 (0.5–0.6)
Asthma	0.6 (0.3–0.8)	0.6 (0.3–0.8)	0.6 (0.4–0.8)	0.7 (0.4–0.9)	0.6 (0.3–0.8)	0.6 (0.6–0.6)
Back complaint*	0.5 (0.3–0.8)	0.6 (0.4–0.8)	0.6 (0.4–0.8)	0.6 (0.4–0.8)	0.6 (0.3–0.8)	0.6 (0.6–0.6)
Sprain/strain*	0.5 (0.3–0.7)	0.5 (0.3–0.7)	0.6 (0.4–0.9)	0.6 (0.4–0.8)	0.4 (0.4–0.5)	0.5 (0.5–0.6)
Total problems managed with clinical treatment	28.7 (27.3–30.2)	30.4 (28.9–31.9)	32.8 (31.1–34.5)	33.5 (31.8–35.2)	32.8 (31.0–34.7)	33.2 (32.5–33.9)

(a) Rate of provision of clinical treatment for selected problem per 100 total encounters.

* Includes multiple ICPC-2 or ICPC-2 PLUS codes (see Appendix 3).

Note: CI—confidence interval.

Table A4.15: Number of encounters where pathology, imaging ordered, summary of annual results BEACH 1998–99 to BEACH 2002–03

	1998–99	1999–00	2000–01	2001–02	2002–03	5 years
	Per cent of encounters (95% CI) (n=96,901)	Per cent of encounters (95% CI) (n=104,856)	Per cent of encounters (95% CI) (n=99,307)	Per cent of encounters (95% CI) (n=96,973)	Per cent of encounters (95% CI) (n=100,987)	Per cent of encounters (95% CI) (n=502,100)
No tests ordered	81.9 (81.3–82.5)	81.1 (80.5–81.7)	80.7 (80.1–81.3)	80.8 (80.2–81.4)	79.7 (79.0–80.3)	79.8 (79.5–80.1)
At least one pathology test ordered	13.2 (12.8–13.7)	13.8 (13.3–14.3)	13.8 (13.3–14.3)	14.0 (13.5–14.5)	14.7 (14.2–15.3)	14.9 (14.7–15.1)
At least one imaging ordered	6.3 (6.0–6.6)	6.7 (6.4–7.0)	6.8 (6.5–7.1)	6.9 (6.6–7.2)	7.5 (7.1–7.8)	7.1 (7.0–7.3)

Note: CI—confidence interval.

Table A4.16 (a): Distribution of pathology orders across pathology groups, summary of annual results BEACH 1998–99 to BEACH 2000–01

	1998–99	1999–00	2000–01 ^(a)
Pathology test ordered	Rate per 100 encounters (95% CI) (n=96,901)	Rate per 100 encounters (95% CI) (n=104,700)	Rate per 100 encounters (95% CI) (n=99,307)
Chemical	11.3 (10.6–11.9)	12.1 (11.4–12.8)	15.4 (14.6–16.2)
Haematology	5.1 (4.8–5.4)	5.1 (4.8–5.4)	5.7 (5.3–6.0)
Microbiology	4.1 (3.8–4.4)	4.6 (4.3–4.9)	4.5 (4.2–4.7)
Cytology	1.6 (1.3–1.8)	1.5 (1.3–1.8)	1.5 (1.2–1.8)
Other NEC	1.3 (0.9–1.7)	1.6 (1.2–2.0)	1.1 (0.8–1.3)
Infertility/pregnancy	0.5 (0.3–0.6)	0.4 (0.2–0.6)	0.3 (0.0–0.6)
Tissue pathology	0.4 (0.3–0.6)	0.5 (0.3–0.7)	0.5 (0.2–0.7)
Immunology	0.4 (0.1–0.7)	0.5 (0.2–0.8)	0.5 (0.3–0.8)
Simple test; other	0.0 (0.0–0.4)	0.0 (0.0–0.7)	0.1 (0.0–0.5)
Total pathology tests	24.6 (23.6–25.7)	26.3 (25.2–27.5)	29.4 (28.2–30.7)

(a) Data collection method and coding system changed at the end of the third year of BEACH. Years 1 and 2 are not comparable with years 3 to 5.

Note: CI—confidence interval.

Table A4.16 (b): Distribution of pathology orders across pathology groups, summary of annual results BEACH 2000–01 to BEACH 2002–03

Pathology test ordered	2000–01 ^(a)	2001–02	2002–03	3 years
	Rate per 100 encs (95% CI) (n=99,307)	Rate per 100 encs (95% CI) (n=97,973)	Rate per 100 encs (95% CI) (n=100,987)	Rate per 100 encs (95% CI) (n=297,267)
Chemical	15.7 (14.8–16.5)	16.5 (15.6–17.3)	17.7 (16.8–18.6)	16.6 (16.1–17.1)
Haematology	5.8 (5.5–6.2)	6.2 (5.8–6.5)	6.3 (5.9–6.6)	6.1 (5.9–6.3)
Microbiology	4.6 (4.3–4.9)	4.9 (4.5–5.2)	5.1 (4.8–5.5)	4.9 (4.7–5.0)
Cytology	1.5 (1.2–1.8)	1.6 (1.3–1.8)	1.7 (1.4–1.9)	1.6 (1.4–1.7)
Other NEC	0.8 (0.4–1.1)	0.7 (0.5–0.9)	0.8 (0.4–1.1)	0.7 (0.6–0.9)
Infertility/pregnancy	0.3 (0.0–0.6)	0.3 (0.1–0.5)	0.3 (0.1–0.5)	0.3 (0.1–0.4)
Tissue pathology	0.5 (0.2–0.7)	0.5 (0.1–0.8)	0.5 (0.2–0.8)	0.5 (0.3–0.7)
Immunology	0.5 (0.2–0.8)	0.5 (0.3–0.7)	0.5 (0.2–0.7)	0.5 (0.3–0.6)
Simple test; other	0.1 (0.0–0.5)	0.1 (0.0–0.4)	0.1 (0.0–0.4)	0.1 (0.0–0.3)
Total pathology tests	29.7 (28.4–30.9)	31.0 (29.7–32.4)	32.9 (31.5–34.4)	31.2 (30.4–32.0)

(a) Data collection and coding method changed at the end of the third year of BEACH. Years 1 and 2 are not comparable with years 3 to 5.

Note: Encs—encounters; CI—confidence interval.

Table A4.17 (a): Most frequent imaging tests ordered, BEACH 1998–99 and 1999–00

Imaging test ordered	1998–99	1999–00 ^(a)
	Rate per 100 encounters (95% CI) (n=96,901)	Rate per 100 encounters (95% CI) (n=104,856)
Plain	4.3 (4.0–4.5)	4.4 (4.2–4.7)
Contrast/US/CT	2.5 (2.3–2.6)	2.6 (2.4–2.8)
Other	0.3 (0.1–0.5)	0.5 (0.2–0.7)
Total imaging tests	7.1 (6.7–7.4)	7.5 (7.1–7.8)

(a) Data collection and coding method changed at the end of the second BEACH year. Years 1 and 2 are not comparable with years 3 and 4.

Note: CI—confidence interval.

Table A4.17 (b): Most frequent imaging tests ordered BEACH 2000–01 and 2002–03

Imaging test ordered	1999–00 ^(a)	2000–01	2001–02	2002–03	4 years
	Rate per 100 encs (95% CI) (n=104,856)	Rate per 100 encs (95% CI) (n=99,307)	Rate per 100 encs (95% CI) (n=96,973)	Rate per 100 encs (95% CI) (n=100,987)	Rate per 100 encs (95% CI) (n=402,119)
Diagnostic radiology	4.8 (4.5–5.1)	4.8 (4.6–5.1)	4.6 (4.4–4.8)	5.1 (4.9–5.4)	4.8 (4.7–5.0)
Ultrasound	1.9 (1.8–2.1)	2.1 (2.0–2.3)	2.5 (2.3–2.7)	2.6 (2.5–2.8)	2.3 (2.2–2.4)
Computerised tomography	0.6 (0.5–0.8)	0.7 (0.6–0.8)	0.8 (0.6–0.9)	0.8 (0.7–0.9)	0.7 (0.6–0.8)
Nuclear medicine imaging	0.0 (0.0–0.6)	0.0 (0.0–0.4)	0.0 (0.0–0.4)	0.0 (0.0–0.4)	0.0 (0.0–0.2)
Magnetic resonance imaging	0.0 (0.0–0.5)	0.0 (0.0–0.4)	0.0 (0.0–0.5)	0.0 (0.0–0.6)	0.0 (0.0–0.3)
Total imaging tests	7.4 (7.1–7.8)	7.7 (7.3–8.0)	7.9 (7.6–8.2)	8.6 (8.2–9.0)	7.9 (7.7–8.1)

(a) Data collection and coding method changed at the end of the second BEACH year. Years 1 and 2 are not comparable with years 3 and 4.

Note: Encs—encounters; CI—confidence interval.